Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma (Review)

Vale CL, Tierney J, Bull SJ, Symonds PR

www.cochranelibrary.com

WILEY

TABLE OF CONTENTS

[Intervention Review]

Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma

Claire L Vale[1], Jayne Tierney[1], Sarah J Bull[2], Paul R Symonds[3]

[1]Meta-analysis Group, MRC Clinical Trials Unit at UCL, London, UK. [2]Meta-analysis Group, MRC Clinical Trials Unit, London, UK. [3]Department of Oncology, Leicester Royal Infirmary, Leicester, UK

Contact address: Claire L Vale, Meta-analysis Group, MRC Clinical Trials Unit at UCL, Aviation House, 125 Kingsway, London, WC2B 6SE, UK. claire.vale@ucl.ac.uk.

A B S T R A C T

Background

Although endometrial adenocarcinoma is a common gynaecological cancer, a comparatively small proportion of patients present with, or develop, recurrent or advanced disease. However, for those women whose disease does progress or recur the prognosis is poor and the best treatment is yet to be identified. Co-morbidity, including obesity and cardiac disease, and concerns over toxicity have prevented more extensive studies of cytotoxic chemotherapy, although there are a number of active agents.

Objectives

To assess any benefits or adverse effects of cytotoxic chemotherapy in women with advanced, recurrent or metastatic endometrial adenocarcinoma.

Search methods

Systematic searches of MEDLINE, EMBASE, CENTRAL and the Cochrane Gynaecological Cancer specialist trials register were conducted to identify all eligible randomised controlled trials (RCTs).Databases were searched from 1966 to January 2012. Literature searches were supplemented with searches of relevant trials registers and conference proceedings.

Selection criteria

RCTs comparing chemotherapy versus another intervention (including different chemotherapy) in advanced disease were considered. Trials of adjuvant treatment or for sarcomatous tumours were excluded.

Data collection and analysis

Data were extracted from the papers by review authors and authors of included studies contacted for further information.

Main results

Fourteen eligible trials, which recruited patients between 1974 and 2005, were identified, eight of which compared 'more' with 'less' chemotherapy. Results from these eight trials, including 1519 patients, showed that treatment consisting of 'more' chemotherapy was associated with longer overall survival (OS) (hazard ratio (HR) 0.86; 95% confidence intervals (CI) 0.77 to 0.96; P = 0.005) and with longer progression-free survival (PFS) (n = 1526; HR 0.82; 95% CI 0.74 to 0.90; P < 0.0001). However, serious acute toxicities were more common in women randomised to the more-intense chemotherapy regimens.

There was no evidence to suggest that any particular doublet chemotherapy was better (or worse) than any other, or that any single-agent chemotherapy was better (or worse) than another; however, data for these two comparisons were limited. There were no comparative trials of chemotherapy with endocrine therapy or best supportive care alone.

Authors' conclusions

This review suggests that more-intense chemotherapy regimens may improve both OS and PFS for women with advanced or recurrent endometrial cancer. However, owing to inconsistencies between cytotoxic drug combinations that have been assessed in randomised trials to date, the optimum regimen has still to be defined. Future trials should aim to include measures of quality of life (QoL) and symptom control in addition to survival and progression outcomes.

P L A I N   L A N G U A G E   S U M M A R Y

More chemotherapy helps women with advanced endometrial cancer; however, the best combination of chemotherapy drugs is still not clear

Using more chemotherapy drugs in combination seems to help women with advanced or recurrent endometrial cancer to live for longer and to delay the cancer from spreading or getting worse. However, giving these extra drugs may cause more serious short-term side effects. We do not know what effect using more drugs has on long-term side effects, control of symptoms or quality of life because they were poorly studied in the individual trials included in this review.

BACKGROUND

Description of the condition

There were around 280,000 cases of endometrial adenocarcinoma worldwide in 2008 (Jemal 2011); however, there is wide geographical variation. Incidence tends to be highest in more developed areas (12.9 per 100,000 per year) where there were more than 33,000 deaths from the disease in 2008 (Jemal 2011).

Risk factors include chronic exposure to oestrogens such as exogenous unopposed oestrogen used as hormone replacement therapy (HRT), having few children, early onset of menstruation and late menopause. Obesity is a risk factor owing to conversion of precursor hormones to oestrogen in peripheral fat cells and rising rates of obesity in affluent countries may result in an increasing incidence of endometrial cancer. Diabetes seems to be a separate risk factor. Trials of adjuvant tamoxifen given to women being treated for breast cancer have shown that there is an increased risk of endometrial cancer from using tamoxifen (it is a weak oestrogen); an approximate doubling of the risk was seen with one to two years of therapy and a quadrupling of the risk was seen with five years of therapy (EBCTCG 1998).

Ninety per cent of uterine cancers are adenocarcinoma and arise in the endometrium (lining of the uterus). Histological grading is split into three categories; grade I being well differentiated and grade III poorly differentiated (differentiation refers to how abnormal the cells and tissue patterns are). The degree of spread of the tumour is classified according to the Federation of International Gynaecologists and Obstetricians (FIGO) staging system (FIGO 2009). Eighty per cent of women who present with endometrial cancer that has not spread from the uterus have good overall survival (OS). Despite this, certain features identify women with higher risk of recurrence: certain histological subtypes (e.g. papillary serous carcinoma, endometrioid carcinoma and clear cell carcinoma); high grade, deep invasion in the muscle of the uterus; tumour extending to the cervix; spread to lymphatic or blood vessels and extra-uterine disease (Bremond 2001).

Description of the intervention

Optimum treatment for endometrial cancer depends on stage and grade. Almost 90% of women with endometrial cancer are treated by primary surgery with five-year survival rates of over 70%. Adjuvant radiotherapy following surgery may be offered if the risk of local recurrence is high (grade III or stage Ib and above) and adjuvant treatments, such as endocrine therapy or chemotherapy, have been investigated in women at high risk of recurrence. Treatment failure, defined as recurrence or spread to other parts of the body (metastases), is common particularly in women with advanced-stage disease at diagnosis or those with high-risk features in the primary tumour. It is important to distinguish between isolated pelvic relapse and relapse where the cancer has become widespread. The former can be treated by radiotherapy or exenteration surgery, which is an extensive surgical procedure (Morris 1996). The latter requires palliative treatment. About one third of recurrences are localised to the pelvis and two-thirds have spread outside the pelvis (Burke 1990).

Women with local recurrences not amenable to surgery or radical irradiation and those with more extensive spread are considered for systemic therapy, which may be endocrine therapy or cytotoxic chemotherapy, depending on grade and the women's general level of fitness (performance status). These women are not considered curable. The aim of systemic therapy should be palliation (relief) of symptoms, improvement in quality of life (QoL), delaying progression of the disease and extending OS. A Cochrane review of hormone therapy in advanced or recurrent disease (Kokka 2010) found no good evidence to suggest that hormone treatments improve survival for these women. A separate Cochrane review of adjuvant chemotherapy (after hysterectomy) for women presenting with earlier stages of endometrial cancer amenable to surgery showed that chemotherapy may improve survival and prolong disease-free survival for these women (Johnson 2011).

How the intervention might work

Cytotoxic chemotherapy has been used for advanced disease. A number of drugs have shown anti-tumour activity in Phase II clinical trials, including doxorubicin, epirubicin, cisplatin, carboplatin and paclitaxel. However, the optimum combination of drugs is still not known and the full effects of cytotoxic chemotherapy on survival, progression-free survival (PFS), control of symptoms and QoL are not well established (Humber 2007).

Why it is important to do this review

The purpose of this review is to assess the potential role of cytotoxic chemotherapy where the cancer has spread to other parts of the body or where local cancer is no longer treatable with surgery or radiotherapy. It updates the original review carried out by Humber and colleagues (Humber 2007). More recently, interest in giving adjuvant chemotherapy to women with endometrial cancer at high risk of developing metastases has grown (Faust 2010, Johnson 2011). This review may therefore also provide useful insights as to which drugs or combinations of drugs may be appropriate for use in this setting.

OBJECTIVES

To assess:

- the effectiveness of cytotoxic chemotherapy in women with advanced/recurrent/metastatic endometrial adenocarcinoma;
- whether there is a most effective drug and/or combination;
- the adverse effects of treatment;
- the effect of treatment on QoL.

METHODS

Criteria for considering studies for this review

Types of studies

Randomised controlled trials (RCTs) that met the eligibility criteria were considered for inclusion in this review.

Types of participants

We included trials that had randomised women with advanced/recurrent/metastatic endometrial adenocarcinoma (not amenable to potentially curative surgery or radical radiotherapy) who were suitable for cytotoxic chemotherapy.

We excluded trials accruing women who:

- had chemotherapy in an adjuvant setting following potentially curative surgery;
- had uterine carcinosarcoma or sarcoma (these types of cancer behave differently from the common endometrial cancer);
- had earlier stages of endometrial cancer.

Types of interventions

Any cytotoxic chemotherapy versus:

- placebo;
- best supportive care;
- alternative chemotherapy.

For the purposes of this review, cytotoxic chemotherapy is defined as a drug given with the intent of producing tumour regression as defined by World Health Organization (WHO) criteria for assessing response (Miller 1981).

Types of outcome measures

In the original review carried out by Humber and colleagues (Humber 2007), outcomes considered were OS, PFS, QoL, symptom control, acute toxicity and late toxicity. However, since there were insufficient data in that review to assess the effect of treatments on QoL, symptom control or late toxicity, this update also necessarily concentrated on:

- OS;
- PFS;
- 'serious' acute toxicity (grade 3 or greater).

Search methods for identification of studies

Electronic searches

The following electronic databases were searched:

- the Cochrane Gynaecological Cancer Collaborative Review Group's Trial Register
- the Cochrane Central Register of Controlled Trials (CENTRAL; Appendix 1)
- MEDLINE: we developed a search strategy consisting of the highly sensitive search strategy (HSSS) for RCTs as described in the *Cochrane Handbook for Systematic Reviews of Interventions* (Higgins 2011) and terms related to the review topic (Appendix 2).
- EMBASE (Appendix 3)

Databases were searched from 1966 to January 2012.

Searching other resources

For this update, systematic searches of electronic resources were supplemented by handsearching the reference lists of all published eligible trials; abstract searches from relevant conference proceedings, including annual meetings of the American Society of Clinical Oncology (2006 to 2011), and the biennial meetings of the International Gynecologic Cancer Society (2006 to 2010), the European Society for Medical Oncology (2006 to 2010) and the European Society of Gynecological Oncology (2007 to 2011).

Moreover, we searched trials registries including Clinicaltrials.gov, National Cancer Institute's database Physicians Data Query (PDQ at cancer.gov) and the World Health Organization International Clinical Trials Registry for ongoing and closed trials (www.who.int/ictrp/) (no time-limits were placed on searches).

For the original review (2005) authors of relevant trials had been contacted to ask if they knew of further data that may or may not have been published. Papers in all languages were sought and translations carried out if necessary.

Data collection and analysis

Selection of studies

Trials identified by the searches were assessed by two review authors independently for inclusion.

Data extraction and management

Data was also extracted independently from the resulting trials by two review authors. Where there were disagreements between the two review authors these were resolved by discussion or if necessary, through consultation with a third review author. No attempt was made to blind review authors to article authors or journals. Data extracted and documented included:

- method of randomisation and allocation concealment;
- numbers of participants randomised to each arm of the trial;
- number of participants excluded from the analysis in each arm of the trial;
- whether there was an intention-to-treat (ITT) analysis;
- length of follow-up;
- participant characteristics (age, histology, grade, extent of disease, previous therapies, performance status, whether disease lies in an area previously treated by radiotherapy and whether any other first-line treatment had been received);
- type of intervention (e.g. drug, dosage and administration regimen/frequency, planned number of cycles);
- proportions of participants who received all, part or none of the planned treatment, or who experienced delays during treatment;
- hazard ratio (HR) and its variance for survival and PFS or, if these were not reported, other relevant summary statistics or data from Kaplan-Meier curves for their estimation (Parmar 1998; Tierney 2007);
- response rates;
- grades and type of acute toxicity.

Where insufficient data were available in the trial report, study authors were contacted and asked whether they could supply summary data from their trial for inclusion in this review.

Assessment of risk of bias in included studies

Each trial was assessed for risk of bias based on the primary outcome of OS using information from the published trial report supplemented with information supplied by study authors where available.

Measures of treatment effect

For meta-analyses of the time-to-event outcomes of OS and PFS, the most appropriate statistic is the HR. If provided in a trial report

or by the investigators, the HR and associated statistics were used directly in the meta-analysis. Alternatively, they were estimated indirectly from other summary statistics or from data extracted from published Kaplan-Meier curves using the methods described in Parmar 1998 and Tierney 2007.

Where sufficient data were reported, odds ratios (ORs) for each acute toxicity category were calculated from the total number of grade 3 and 4 events in each treatment arm. Where more than one type of toxicity was reported in a given category (e.g. nausea reported separately from vomiting), the most frequent was used.

Data synthesis

For the outcomes of OS and PFS, the estimated log HR and variance for individual trials were combined across all trials using a fixed-effect model to give a pooled HR (Yusuf 1985). This represents the overall risk of an event on the research treatment versus control. Absolute differences in median survival and PFS were estimated using the HR and the average control group median survival or PFS ((median/HR) - median).

For categories of acute toxicity, ORs were calculated for individual studies and were combined across all trials, using a fixed-effect model and indicate the overall odds of a severe toxic event for each type of toxicity in the treatment arm versus the control arm.

Subgroup analysis and investigation of heterogeneity

Eligible trials were grouped within three main categories to facilitate interpretation of results, using the same main categories as in the original review (Humber 2005).

1. More- versus less-intense chemotherapy

- Single chemotherapy agent versus the same agent in combination with one or more additional chemotherapy agents.
- Two chemotherapy agents versus the same two agents in combination with one or more additional agents.
- Combination of any two-agent chemotherapy agents with a combination of more than two chemotherapy agents.

2. Doublet chemotherapy versus alternative doublet chemotherapy

- Two-agents versus two agents (substitution of one of the agents for another, or in one trial, the same two-agents on each arm but administered according to different timing regimens).

3. Single-agent chemotherapy versus alternative single-agent chemotherapy

- A single-agent versus a different single-agent chemotherapy.

R E S U L T S

Description of studies

Results of the search

A total of 3293 references were retrieved via the electronic searches, of which 14 were found to be eligible RCTs. No trials were excluded (Figure 1). Of the 14 eligible trial reports, three gave limited data on the primary end points of S and PFS (Horton 1978; Long 2006; Pawinski 1999). Further information was requested from all authors resulting in additional or updated data being obtained for five trials (Edmonson 1987; Horton 1982; Long 2006; Nomura 2010a; Pawinski 1999).

Figure 1. Study flow diagram.


```
┌─────────────────┐         ┌─────────────────┐
│ 3294 records    │────────▶│ 3216 articles   │
│ screened        │         │ assessed as     │
│                 │         │ ineligible      │
└─────────────────┘         └─────────────────┘
        │
        │                   ┌─────────────────┐
        │                   │ 64 ineligible   │
        │                   │ (32 duplicate   │
        │                   │ citations; 12   │
        │                   │ reviews; 12 not │
        │                   │ RCTs; 3 RCTs    │
        │                   │ in early stage  │
        │                   │ endometrial     │
        │                   │ cancer; 5       │
        │                   │ RCTs in         │
        │                   │ advanced        │
        │                   │ endometrial     │
        ▼                   │ cancer but not  │
┌─────────────────┐         │ making          │
│ 78 abstracts/   │         │ treatment       │
│ full articles   │────────▶│ comparisions    │
│ assessed for    │         │ included in this│
│ eligibility     │         │ review)         │
└─────────────────┘         └─────────────────┘
        │
        ▼
┌─────────────────┐
│ 14 RCTs         │
│ identified as   │
│ eligible for    │
│ inclusion       │
└─────────────────┘
```

Two further studies (NCT00052312; NCT00063999) were identified
via the searches of trial registers; however, as both of these studies
are listed as "Active, not recruiting" and no data are yet available,
they have not been evaluated as part of this review.

Included studies

Comparison 1: Trials of more versus less chemotherapy

Eight of the eligible trials made a comparison of more-intense versus less-intense chemotherapy. These eight trials were grouped according to the treatment comparisons made as follows:

Cisplatin combined with other drugs compared with cisplatin as a single agent

Edmonson 1987: one small trial randomised women to receive cisplatin alone or cisplatin in combination with doxorubicin and cyclophosphamide. Thirty women with histologically confirmed, evaluable, progestin-refractory, metastatic endometrial cancer were recruited into this study between May 1980 and September 1983. All patients randomised were treated and analysed for efficacy. Dose reductions were made for heavily pre-irradiated patients. Patients progressing on cisplatin alone were allowed to cross-over into the combination arm. Additional information on survival, PFS and toxicity from an updated analysis (April 2004) were supplied by the investigators for inclusion in this review.

Doxorubicin combined with other drugs compared with doxorubicin as a single agent

Thigpen 1994: 387 women with histologically documented, advanced or recurrent endometrial carcinoma, not amenable to surgery or radiotherapy were entered into this study between 1979 and 1985. They were randomised to receive treatment with doxorubicin alone or in combination with cyclophosphamide. All patients had been treated with progestins in the past, but none had received prior cytotoxic chemotherapy. A request for further information on the main outcomes was declined by the investigators (2004).

Aapro 2003: 177 patients with advanced, inoperable or recurrent endometrial cancer were recruited into this study between September 1988 and June 1994. They were randomly assigned to receive doxorubicin alone or in combination with cisplatin. One of the patients in the doxorubicin arm had received prior chemotherapy.

Thigpen 2004: 299 women with advanced or recurrent endometrial carcinoma were recruited into this study between December 1988 and December 1992. They were randomised to treatment with doxorubicin alone or in combination with cisplatin. None of the patients had been previously treated with chemotherapy.

Doxorubicin and cisplatin combined with other drugs compared with doxorubicin and cisplatin

Long 2006: 28 women with advanced or recurrent endometrial carcinoma were entered into this trial between March 1992 and December 1993. They were randomised to receive doxorubicin and cisplatin or doxorubicin, cisplatin, methotrexate and vinblastine. None of the patients had received prior chemotherapy.

Fleming 2004a: 273 women with either stage III to IV or recurrent endometrial cancer were registered for this study between December 1998 and August 2000. Women were randomised to receive treatment with doxorubicin and cisplatin or doxorubicin, cisplatin and paclitaxel (plus granulocyte colony-stimulating factor, G-CSF) support. None of the patients had received prior chemotherapy.

Three-drug combination chemotherapy (plus hormones) compared with two-drug combination chemotherapy (plus hormones)

Cohen 1984: 295 women with advanced or recurrent endometrial adenocarcinoma were recruited into this study between May 1977 and October 1979. Patients were required to have primary stage III, stage IV, recurrent or residual endometrial adenocarcinoma considered incurable by radiation or surgery alone or in combination. Patients were excluded if they had received prior cytotoxic chemotherapy. Patients were randomised to melphalan, 5-fluorouracil (5-FU) and megestrol or doxorubicin, cyclophosphamide, 5-FU and megestrol.

Horton 1982: 131 women with either histologically confirmed stage III to IV, recurrent or metastatic adenocarcinoma of the uterine corpus, who were not candidates for surgery or radiotherapy, were recruited between January 1977 and June 1979. Patients were randomised to receive either cyclophosphamide, doxorubicin and megestrol or cyclophosphamide, doxorubicin, 5-FU and megestrol. Additional data, from updated ITT analyses of acute toxicity, OS and PFS were supplied by the investigators for inclusion in this review (February 2011). One patient (in the control arm) had received chemotherapy previously.

Comparison 2: Trials comparing different chemotherapy doublets

Four of the 14 eligible trials compared different two-drug regimens (or doublets) or different treatment scheduling of a common doublet (Gallion 2003). One three-arm trial, comparing three separate chemotherapy doublets, was split into two separate comparisons (Nomura 2010a; Nomura 2010b) both including a common 'control' arm for the purposes of the review.

Trials comparing different two-drug combinations

Fleming 2004b: 328 patients with stage III to IV or recurrent endometrial carcinoma were enrolled between August 1996 and November 1998. Prior treatment with hormones, but not chemotherapy, was permitted. Women were randomised to receive doxorubicin and cisplatin or doxorubicin, paclitaxel and G-CSF support.

Nomura 2010a/Nomura 2010b: 90 eligible patients with primary stage III to IV or recurrent endometrial carcinoma were enrolled between February 2003 and May 2005. Women were randomised to receive one of three treatment regimens: docetaxel and cisplatin, docetaxel and carboplatin or paclitaxel and carboplatin. After randomisation two of the 90 patients were excluded (prior to treatment) as they did not have measurable lesions. Twenty-nine patients had received prior chemotherapy treatment. Additional data on OS and PFS were provided by the investigators for inclusion in this update (January 2011). For the purposes of the review, we have made two separate comparisons of docetaxel and cisplatin versus docetaxel and carboplatin (Nomura 2010a) and of paclitaxel and carboplatin versus docetaxel and carboplatin (Nomura 2010b).

Weber 2003: 70 patients with advanced or recurrent endometrial carcinoma were enrolled between 1997 and 2002. Women were randomised to receive doxorubicin and cisplatin or carboplatin and paclitaxel. Additional data regarding OS and PFS were requested (January 2011); however, it was declined by the investigators.

Trials comparing different scheduling of the same two-drug combination

Gallion 2003: 352 women with primary stage III to IV or recurrent endometrial carcinoma were entered between March 1993 and August 1996. Those who had received prior cytotoxic chemotherapy, more than one prior biological therapy or prior radiotherapy in the previous three months were not eligible. Women were randomised to receive doxorubicin and cisplatin, either as a standard-timed or circadian-timed schedule.

Comparison 3: Trials comparing different single agents

Two remaining eligible trials compared different single-agent chemotherapies:

Horton 1978: 47 women with histologically confirmed endometrial cancer with measurable local extension or metastases not amenable to cure by surgery or radiotherapy were recruited into this study. The trial opened in 1974, but the closing date is unknown. Women were randomised to receive doxorubicin or cyclophosphamide. None of the patients had previously been treated with chemotherapy. Neither OS or PFS were reported and the investigators have confirmed that no further data are available (January 2011).

Pawinski 1999: 74 women with histologically confirmed adenocarcinoma of the endometrium and evidence of recurrent or metastatic disease were randomised to receive cyclophosphamide or ifosfamide between June 1987 and May 1994. Approximately half the patients had received prior chemotherapy. Additional ITT analyses of OS, PFS and acute toxicity were supplied by the investigators for inclusion in this review (February 2011).

Full details of the chemotherapy regimens used in the trials may be found in the Characteristics of included studies table.

Excluded studies

No eligible trials were excluded from this review. However, two trials were reported with insufficient outcome data to allow them to be included in the analyses (Horton 1978; Weber 2003).

Risk of bias in included studies

Allocation

Ten trials gave details of the method of randomisation; seven trials described the sequence generation (Aapro 2003; Fleming 2004b; Gallion 2003; Horton 1982; Long 2006; Nomura 2010a; Thigpen 2004). Three trials described the stratification factors used (Cohen 1984; Edmonson 1987; Horton 1978), giving little indication of biased allocation; however, details of allocation concealment were only described adequately in four reports (Fleming 2004a; Fleming 2004b; Gallion 2003; Thigpen 2004). This may reflect a potential bias or simply be because of inadequate reporting.

Blinding

Owing to the nature of the treatments being used, it was not possible for the participants and personnel in these trials to be blinded to the treatment allocations. The outcome assessment was also not blinded; however, for the primary outcome of OS, this is not likely to introduce bias.

Incomplete outcome data

Four studies did not exclude any randomised patients from the analyses (Horton 1982; Long 2006; Pawinski 1999; Weber 2003) and a further eight studies excluded only a small percentage of patients from the analyses (Aapro 2003; Edmonson 1987; Fleming 2004a; Fleming 2004b; Gallion 2003; Nomura 2010a; Nomura 2010b; Thigpen 1994; Thigpen 2004). Two studies (Cohen 1984; Horton 1978) excluded 13% and 15% of the total randomised patients from the reported analyses; however, in both cases, the exclusions were reported to be balanced by arm and therefore may be less likely to introduce bias in the results. Full details of these exclusions are given in the Characteristics of included studies table.

Selective reporting

None of the protocols for included studies were available to check the planned outcomes of the studies. However, all but two studies (Horton 1978; Weber 2003) reported the outcomes of interest for this review in sufficient detail to be included in the analyses.

Effects of interventions

The complete, partial and overall response rates; median PFS/interval and median survival for all RCTs are summarised in Table 1, Table 2 and Table 3.

Comparison 1: trials of more versus less chemotherapy

Overall, the trials of more versus less chemotherapy tended to be well balanced with respect to well-known prognostic factors such as age, stage and performance status with median age across all studies ranging from 63 to 67 years (Table 1). However, in one study (Edmonson 1987) a slightly higher proportion of women had received prior radiation in the treatment arm. In two studies, there was a higher proportion of poorly differentiated, grade III tumours in the control arm (Edmonson 1987; Thigpen 1994).

Although not pre-specified as an outcome, the objective response rate tended to be improved in the 'more' chemotherapy arms, compared with less chemotherapy in all except two of the trials (Cohen 1984; Horton 1982; Table 1). However, these differences were only statistically significant for two of the trials (Fleming 2004a; Thigpen 2004).

Overall survival

For the main outcomes of OS, data were available for all eight trials, including 1519 patients. Across the trials there was a significant 14% reduction the risk of death with more chemotherapy compared with less chemotherapy (HR 0.86; 95% CI 0.77 to 0.96; P = 0.005; Analysis 1.1), with little evidence of heterogeneity (P = 0.90; I^2 = 0%). This represents a potential absolute improvement in absolute survival of about 1.5 months (from 9 to 10.5 months).

Despite differences in the drugs and combinations included in these trials, there was no suggestion that the results varied between subgroups (test for interaction P = 0.69). While the results for each subgroup tended towards favouring more treatment, only one of the subgroups had a significant treatment effect (doxorubicin and cisplatin in combination with other drugs compared with doxorubicin and cisplatin alone). However, as this result was based on only two trials, including 291 patients, it should be treated with caution.

Progression-free survival

Progression data were available for all eight trials, including 1526 patients; however, three studies (Aapro 2003; Cohen 1984; Thigpen 1994) reported only time to progression and not PFS. While the results from these trials were combined with the PFS results of the remaining trials, they may give a somewhat different estimate of the effect of treatment, since deaths were censored rather than included as events. Overall the HR of 0.82 (95% CI 0.74 to 0.90) across trials shows a highly significant 18% relative improvement in the time to progression/PFS with the more-intense regimens compared to the less-intense regimens (P < 0.0001), which suggests an absolute improvement of approximately one month (from six to seven months).

The results across all trials tended to favour more chemotherapy and there was no strong evidence that the results varied either between individual trials (heterogeneity P = 0.23; I^2 = 25%) or between trial subgroups (test for interaction P = 0.19). However, the trial subgroup that compared doxorubicin and cisplatin plus other drugs versus doxorubicin and cisplatin alone and that comparing doxorubicin in combination with other drugs versus doxorubicin alone had results that were significantly in favour of the more chemotherapy arm (Analysis 1.2).

Acute toxicity

To assess toxicity, three trials used the National Cancer Institute Common Toxicity Criteria (NCI CTC), either version 1 (Edmonson 1987; Long 2006), or version 2 (Fleming 2004a). Four trials used either the WHO/Eastern Cooperative Oncology Group (ECOG) (Aapro 2003; Thigpen 1994) or the Gynecologic Oncology Group (GOG) criteria (Cohen 1984; Thigpen 2004). One further trial did not state which scale was used (Horton 1982). However, as all trials used a 5-point system where 0 was no toxicity and 5 was toxicity-related death, it was appropriate to combine data across all trials.

Data on serious (i.e. grade 3 or 4) nausea and vomiting, diarrhoea/other GI toxicity, white blood cell toxicity, thrombocytopenia, anaemia and alopecia were available in sufficient detail for formal analyses. Grade 3-4 cardiotoxicity, fever/infection, neurological toxicity, stomatatis/mucositis and renal/genitourinary toxicity were reported less frequently or for fewer trials, possibly as their occurrence depends on the individual drugs being given. Thus formal analyses of these types of toxicity would be unreliable and were not completed.

Across all trials, serious nausea and vomiting more than doubled with the more-intense regimens compared with less-intense chemotherapies (OR 2.64; 95% CI 1.71 to 4.09; P < 0.00001; Analysis 1.3). While the results appeared fairly consistent across all trials (heterogeneity P = 0.21; I^2 = 32%), they did vary between the trial subgroups. For diarrhoea/other GI toxicities, although there were few grade 3 or 4 events overall (n = 31), there seemed to be an excess with more chemotherapy compared to less chemotherapy (OR 2.25; 95% CI 1.09 to 4.63; Analysis 1.4).

Results for serious white blood cell toxicities (including leukopenia, neutropenia and granulocytopenia) were much more variable from trial to trial (heterogeneity P < 0.0001; I^2 = 89%), and by trial subgroup (test for interaction P < 0.00001) such that it did not seem reasonable to pool these results using either a fixed- or a random-effects model (Analysis 1.5). The effects of more chemotherapy

on serious thrombocytopenia were similarly varied between trials (heterogeneity P < 0.00001; I^2 = 91%) and subgroups (test for interaction P < 0.0001; Analysis 1.6) and so results across all trials were not pooled.

Although based on data from only one trial (Thigpen 2004; total number of events 35), serious anaemia was increased (OR 5.32; 95% CI 2.62 to 10.81; P < 0.0001) with more chemotherapy (Analysis 1.7). Serious alopecia was also increased with more chemotherapy (OR 1.86; 95% CI 1.01 to 3.42; P = 0.05; Analysis 1.8); however, this is based on data from only two trials and the events were dominated by one of those trials (Aapro 2003) that compared doxorubicin alone and in combination.

Across all trials, 19 patients were reported to have died owing to treatment-related toxicity; however, not all trials reports whether these deaths were in the more or less chemotherapy arms. In addition, a number of trials reported that toxicity was a factor that led to protocol violations or discontinuation of treatment. Cohen 1984 stated that 35/107 patients with serious haematological toxicity had protocol violations; Aapro 2003 reported that 10% of patients receiving more chemotherapy and 2% of those receiving less chemotherapy stopped treatment due to "extensive toxicity" and Fleming 2004a reported that 32/134 patients (24%) receiving more chemotherapy and 12/129 patients (9%) receiving less chemotherapy discontinued treatment due to toxicity.

Comparison 2: trials comparing different chemotherapy doublets

Overall, the trials included in this comparison tended to be well balanced with respect to well-known prognostic factors such as age, stage and performance status with median age across all studies ranging from 61 to 66 years (Table 2). However, one study (Fleming 2004b) reported that patients were not well balanced by age. There were no significant differences reported between the treatment arms for any of the trials in terms of objective response rates and both the median OS and PFS times were also similar between the treatment arms for all of the trials (Table 2). For one trial (Weber 2003) insufficient outcome data were available for formal analyses of any of the outcomes.

For the three remaining trials in this comparison, there was no evidence that any of the treatment comparisons made differed in terms of either OS (Analysis 2.1) or PFS (Analysis 2.2). Because the treatment comparisons being made between the studies varied widely in terms of the chemotherapy doublets being investigated, no overall effect was calculated.

Acute toxicity was assessed using GOG criteria for two trials (Fleming 2004b; Gallion 2003) and using NCU CTC version 2 for one further trial (Nomura 2010a; Nomura 2010b). All three trials reported that the major toxicities in both arms were haematological (leukopenia or granulocytopenia). In two trials (Fleming 2004b; Nomura 2010a; Nomura 2010b), while the rates of grade 3 to 4 haematological toxicity were in excess of 70% overall, there was no significant difference between the treatment arms. In the third trial (Gallion 2003), rates were similarly high (> 70% overall); however, there was a significant difference in the rates of both leukopenia (P = 0.01) and granulocytopenia (P = 0.04) that favoured the circadian treatment schedule.

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

The most common serious non-haematological toxicity for all three trials was gastrointestinal toxicity. Gallion 2003 and Nomura 2010a; Nomura 2010b reported levels of nausea and vomiting of 14% and 9% overall (respectively) and Fleming 2004b reported rates for all grade 3 to 4 gastrointestinal symptoms of 14%. No significant differences were reported between the treatment arms for any of the studies.

Across all four trials in this comparison, 17 patients were reported to have died due to treatment-related toxicity, most commonly due to renal failure (four deaths) and sepsis (seven deaths). In addition, Fleming 2004b reported that 48 patients (30% of the total randomised) stopped treatment due to toxicity although the numbers stopping treatment were very similar on the two treatment arms.

Comparison 3: trials comparing different single agents

This comparison includes two trials (Horton 1978; Pawinski 1999) that compared different single-agent chemotherapy regimens (Table 3). However, data for inclusion in this meta-analysis were only available for one trial (Pawinski 1999) that randomised only 74 patients. There was no evidence of a difference in terms of OS (Analysis 3.1) or PFS (Analysis 3.2) between the treatment arms. The most commonly reported serious toxicities for this trial were nausea and vomiting, and alopecia. Grade 3 nausea and vomiting was reported for 20 patients (27%) overall, with no difference between the treatment arms. Grade 3 alopecia was reported for 12 patients (16% of the total randomised) receiving ifosfamide and six patients (8% of the total randomised) receiving cyclophosphamide.

No deaths were reported as being due to treatment-related toxicity for either trial; however, toxicity was cited as the reason that three patients discontinued treatment in one trial (Pawinski 1999).

DISCUSSION

Summary of main results

Our searches identified 14 RCTs, randomising 2525 women, of cytotoxic chemotherapy in advanced or recurrent endometrial adenocarcinoma. The apparent quality of these trials based largely on the trial reports was variable. For example, it is not known how randomisation occurred in a number of the studies and the method of concealment of allocation generally was not reported. Three trials randomised fewer than 50 patients (Edmonson 1987; Horton 1978; Long 2006) and so would only be sufficiently powered to detect a very large difference in the effectiveness between the two arms. Two studies were stopped prematurely (Aapro 2003; Long 2006). Aapro 2003 cited a dramatic fall in recruitment after the publication results of Thigpen 2004 in abstract form as the reason for early termination. Long 1995 stopped early after only accruing 28 patients, at a slow rate. Furthermore, some trials excluded relatively large numbers of patients after randomisation such that analyses were not always on an "intention-to-treat" basis. Therefore, the possibility of some bias in the estimates of treatment effect cannot be ruled out. Trials were grouped into three main comparisons according to the broad comparisons made. The majority (8 trials, 1571 women) compared more versus less chemotherapy and this review largely focused on the results of this comparison.

Across the eight trials comparing more- versus less-intense chemotherapy, the results for both OS and PFS were consistent across the trial groups and in favour of the more-intensive chemotherapy regimens. As the control arms for some of these trials are the comparators for others, it is not possible from these results to recommend a particular regimen. However, in terms of survival and PFS, three or more drug combinations including doxorubicin and cisplatin seemed better than the two-drug combination of doxorubicin and cisplatin, which in turn appeared to improve upon single-agent doxorubicin chemotherapy. However, more chemotherapy was generally associated with increased rates of serious acute toxicities, most commonly haematological and gastrointestinal. Survival benefits should therefore be considered alongside these increases in toxicity, in particular as advanced endometrial cancer tends to affect more elderly women often with other co-morbidities. While two trials reported increases in alopecia, as may be expected with doxorubicin-based regimens, there was a lack of alopecia data reported in trials using paclitaxel-containing regimens, where alopecia may also be expected to be common.

The data does not allow any conclusions to be made about which patients may potentially gain the greatest benefits from chemotherapy. The randomised trials enrolled a heterogeneous group of patients in terms of prior therapies, which included hormonal agents, radiotherapy and cytotoxic agents, may have impacted on the response to chemotherapy in this advanced setting. The trials also included patients with both advanced and recurrent disease and there may be differences between these patient groups in terms of how well they respond to treatments. These and other factors including performance status and other co-morbidities may impact on how much benefit a patient obtains from treatment as well as how they tolerate more-intensive chemotherapy. There are no data regarding correlation between sites of metastatic disease and benefit (e.g. any metastases versus visceral metastases). There is therefore little evidence base from randomised studies to help guide initial choice of therapy, be it endocrine, chemotherapy or best supportive care.

There was no good evidence from the RCTs comparing other chemotherapy regimens or scheduling, that any were superior in terms of improved survival and PFS and/or reduced toxicity; however, insufficient data and inconsistent 'control' arm treatments between the trials comparing different two-drug combinations makes any conclusion difficult. Moreover, these modestly sized trials are unlikely to be adequately powered to discriminate between the treatment arms. Only two trials compared single-agent chemotherapies and these are possibly now outdated. While traditionally, doxorubicin has been the most common drug used in the treatment of endometrial cancer, more recently, paclitaxel and carboplatin have become more widely used, possibly as a result of their routine use in the treatment of ovarian and, increasingly, cervical cancer. Results of one of the currently active trials (NCT00063999) may help to determine whether this two-drug combination improves on doxorubicin-based treatment for women with advanced endometrial cancer.

As no QoL data were collected or reported in any of the trials, we cannot draw any conclusions on the potential of chemotherapy to palliate symptoms and improve QoL, although these are clearly important priorities for both patients and clinicians. Given the modest impact of chemotherapy on PFS and OS, collection of such patient-reported data must be a priority in future research. Reduction in tumour volume may lead to symptomatic benefit,

but because such gains may be offset by treatment-related toxicity from treatment, it is sensible to try to assess effects on QoL in a systematic way in trials of palliative therapy. Reproducible scoring systems are available for assessing both symptoms and global QoL. Trials in other tumour types such as non-small cell lung cancer have used such scoring systems and demonstrated significant improvements in QoL, even where survival benefits were small (Cullen 1999).

AUTHORS' CONCLUSIONS

Implications for practice

More-intensive cytotoxic chemotherapy regimens, with drugs including cisplatin, carboplatin, doxorubicin and taxanes may improve OS and PFS in women with advanced, metastatic or recurrent endometrial adenocarcinoma. However, the optimal treatment regimen is still unclear and benefits are at the expense of increased acute toxicity. These issues should be discussed with patients before they consent to chemotherapy and where possible, patients should be offered entry into well-designed RCTs of treatment.

No single-agent or combination chemotherapy stands out. However, our results suggest the combination of up to three drugs, including doxorubicin, may be a reasonable choice. Two active studies identified in our searches (NCT00052312; NCT00063999) are evaluating the use of the three-drug combination of doxorubicin, cisplatin and paclitaxel, albeit that the comparators differ between the two studies, with one using doxorubicin and cisplatin (NCT00052312) and the other using paclitaxel and carboplatin (NCT00063999). Results of these two studies, once available, may help to define an optimal treatment regimen for women with advanced disease.

Implications for research

Despite the involvement of over 2500 women in randomised trials, basic questions have not been answered. While the results of this review demonstrate improvements in survival and PFS with some of the more-intensive chemotherapy regimens in women with advanced, recurrent or metastatic endometrial adenocarcinoma, there may remain a need to randomise women with advanced, recurrent and metastatic disease to receive chemotherapy, hormone therapy or best supportive care and to assessment properly the impact of treatment within subgroups of patients defined by the stage or extent of disease, prior treatments and baseline characteristics that may influence the response to treatment. In this way, patients most likely to benefit may be defined thus reducing unnecessary harms and side effects for those women less likely to benefit. Furthermore, QoL and symptom scores should supplement outcomes such as response, progression and OS.

REFERENCES

References to studies included in this review

Aapro 2003 *{published data only}*

Aapro M, Bolis G, Chevallier B, van der Burg MEL, Poveda A, de Oliveira C, et al. An EORTC-GCCG randomized phase II trial of doxorubicin versus dox-cisplatin (cDDP) in endometrial carcinoma. Proceedings of the Annual Meeting of the American Society of Clinical Oncology. 1994; Vol. 13, issue Abstract 885:275.

* Aapro MS, van Wijk FH, Bolis G, Chevallier B, van der Burg MEL, Poveda A, et al on behalf of the EORTC-GCCG. Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC-GCCG. *Annals of Oncology* 2003;**14**:441-8.

Cohen 1984 *{published and unpublished data}*

Cohen CJ, Bruckner HW, Deppe G, Blessing JA, Homesley H, Lee JH, et al. Multidrug treatment of advanced and recurrent endometrial carcinoma: a Gynecologic Oncology Group study. *Obstetrics and Gynecology* 1984;**63**(5):719-26.

Edmonson 1987 *{published and unpublished data}*

Edmonson JH, Krook JE, Hilton JF, Malkasian GD, Everson LK, Jefferies JA, et al. Randomized phase II studies of cisplatin and a combination of cyclophosphamide-doxorubicin-cisplatin (CAP) in patients with progestin-refractory advanced endometrial carcinoma. *Gynecologic Oncology* 1987;**28**(1):20-4.

Fleming 2004a *{published data only}*

* Fleming GF, Brunetto VL, Cella D, Look KY, Reid GC, Munkarah AR, et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. *Journal of Clinical Oncology* 2004;**22**(11):2159-66.

Fleming GF, Brunetto VL, Mundt AJ, Burks RT, Look KY, Reid G. Randomised trial of doxorubicin (DOX) plus cisplatin (CIS) versus DOX plus CIS plus paclitaxel (TAX) in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group (GOG) study. Proceedings of American Society of Clinical Oncology. 2002; Vol. 21:202a Abstract 807.

Fleming 2004b *{published data only}*

* Fleming GF, Filiaci VL, Bentley RC, Herzog T, Vaccarello L, Gallion H. Phase III randomised trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. *Annals of Oncology* 2004;**15**:1173-8.

Gallion 2003 *{published data only}*

* Gallion HH, Brunetto VL, Cibull M, Lentz SS, Reid G, Soper JT, et al. Randomized phase III trial of standard timed doxorubicin plus cisplatin versus circadian timed doxorubicin plus cisplatin in stage III and IV or recurrence endometrial carcinoma: a Gynecologic Oncology Group study. *Journal of Clinical Oncology* 2003;**21**(20):3808-13.

Horton 1978 *{published data only}*

Horton J, Begg CB, Arseneault J, Bruckner H, Creech R, Hahn RG. Comparison of adriamycin with cyclophosphamide in patients with advanced endometrial cancer. *Cancer Treatment Reports* 1978;**62**(1):159-61.

Horton 1982 *{published and unpublished data}*

Horton J, Elson P, Gordon P, Hahn R, Creech R. Combination chemotherapy for advanced endometrial cancer. An evaluation of three regimens. *Cancer* 1982;**49**:2241-5.

Long 2006 *{published data only}*

Long HJ, Nelimark RA, Cha SS. Comparison of methotrexate, vinblastine, doxorubicin and cisplatin (MVAC) vs doxorubicin and cisplatin (AC) in advanced endometrial carcinoma. Proceedings of the Annual Meeting of the American Society of Clinical Oncology. 1995; Vol. 14:282 Abstract 797.

Long III H, Nelimark R, Podratz K, Suman V, Keeney G, Nikcevich D, et al. Phase III comparison of methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) vs. doxorubicin and cisplatin (AC) in women with advanced primary or recurrent metastatic carcinoma of the uterine endometrium. *Gynecologic Oncology* 2006;**100**:501-5.

Nomura 2010a *{published and unpublished data}*

Nomura H, Aoki D, Takahashi F, Katsumata N, Watanabe Y, Konishi I, et al. Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: Japanese Gynecologic Oncology Group trial (JGOG2041). Journal of Clinical Oncology (ASCO Meeting Abstracts). 2008; Vol. 26:16526.

* Nomura H, Aoki D, Takahashi F, Katsumata N, Watanabe Y, Konishi I, et al. Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: a Japanese Gynecologic Oncology Group study (JGOG2041). *Annals of Oncology* 2011;**22**(3):636-42.

Nomura 2010b *{published and unpublished data}*

Nomura H, Aoki D, Takahashi F, Katsumata N, Watanabe Y, Konishi I, et al. Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: Japanese Gynecologic Oncology Group trial (JGOG2041). Journal of Clinical Oncology (ASCO Meeting Abstracts). 2008; Vol. 26:16526.

Nomura H, Aoki D, Takahashi F, Katsumata N, Watanabe Y, Konishi I, et al. Randomized phase II study comparing docetaxel plus cisplatin, docetaxel plus carboplatin, and paclitaxel plus carboplatin in patients with advanced or recurrent endometrial carcinoma: a Japanese Gynecologic Oncology Group study (JGOG2041). *Annals of Oncology* 2011;**22**(3):636-42.

Pawinski 1999 *{published and unpublished data}*

Pawinski A, Tumolo S, Hoesel G, Cervantes A, van Oosterom AT, Hoctin Boes G, et al. Cyclophosphamide or ifosfamide

in patients with advanced and/or recurrent endometrial carcinoma: a randomised phase II study of the EORTC Gynecological Cancer Cooperative Group. *European Journal of Obstetrics and Gynecology and Reproductive Biology* 1999;**86**:179-83.

Thigpen 1994 *{published data only}*

Thigpen J, Blessing P, DiSaia P, Ehrlich C for the Gynecologic Oncology Group. A randomized comparison of adriamycin with or without cyclophosphamide in the treatment of advanced or recurrent endometrial carcinoma. Proceedings of the American Society of Clinical Oncology. 1985:115 Abstract C-448.

* Thigpen JT, Blessing JA, DiSaia PJ, Yordan E, Carson LF, Evers C. A randomized comparison of doxorubicin alone versus doxorubicin plus cyclophosphamide in the management of advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group study. *Journal of Clinical Oncology* 1994;**12**(7):1408-14.

Thigpen 2004 *{published data only}*

* Thigpen JT, Brady MF, Homesley, Malfetano J, DuBeshter B, Burger RA, et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: a Gynecologic Oncology Group Study (GOG). *Journal of Clinical Oncology* 2004;**22**(19):3902-8.

Thigpen T, Blessing J, Homesley H, Malfetano J, DiSaia P, Yordan E. Phase III trial of doxorubicin ± cisplatin in advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group (GOG) study. Proceedings of the American Society of Clinical Oncology. 1993; Vol. 12:261 Abstract 830.

Weber 2003 *{published data only}*

Weber B, Mayer F, Bougnoux P, Lesimple T, Joly F, Fabbro M, et al. What is the best chemotherapy regimen in recurrent or advanced endometrial carcinoma? Preliminary results. Proceedings of the American Society of Clinical Oncology. 2003; Vol. 22:Abstract 1819.

References to ongoing studies

NCT00052312 *{unpublished data only}*

Reed NS (Investigator). Doxorubicin and cisplatin with or without paclitaxel in treating patients with locally advanced, metastatic and/or relapsed endometrial cancer. http://clinicaltrials.gov/ct2/show/record/NCT00052312.

NCT00063999 *{unpublished data only}*

Miller D (Protocol chair). Randomized phase III trial of doxorubicin/cisplatin/paclitaxel and G-CSF versus carboplatin/paclitaxel in patients with stage III and IV or recurrent endometrial cancer. http://clinicaltrials.gov/ct/show/NCT0006399.

Additional references

Bremond 2001

Bremond A, Bataillard A, Thomas L, Achard JL, Fervers B, Fondrinier E, et al. Cancer of the endometrium. *British Journal of Cancer* 2001;**84**(supple 2):31-6.

Burke 1990

Burke TW, Heller PB, Woodward J, Davidson SA, Hoskins WJ, Park RC, et al. Treatment failure in endometrial carcinoma. *Obstetrics and Gynaecology* 1990;**75**:96-101.

Cullen 1999

Cullen MH, Woodroffe CM, Billingham LJ, Chetiyarwardana AD, Joshi R, Ferry D, et al. Mitomycin, ifosfamide and cisplatin (MIC) in unresectable non-small cell lung cancer: effects on survival and quality of life. *Journal of Clinical Oncology* 1999;**17**(10):3188-94.

EBCTCG 1998

Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. *The Lancet* 1998;**351**:1451-67.

Faust 2010

Faust G, Davies Q, Symonds P. Changes in the treatment of endometrial cancer. *British Journal of Obstetrics and Gynaecology* 2010;**117**:1043-6.

FIGO 2009

Creasman W. Revised FIGO staging for carcinoma of the endometrium. *International Journal of Gynaecology and Obstetrics* 2009;**105**(2):109.

Jemal 2011

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global Cancer Statistics. *CA: Cancer Journal for Clinicians* 2011;**61**:69-90.

Johnson 2011

Johnson N, Bryant A, Miles T, Hogberg T, Cornes P. Adjuvant chemotherapy for endometrial cancer after hysterectomy. *Cochrane Database of Systematic Reviews* 2011, Issue 10. [DOI: 10.1002/14651858.CD003175.pub2]

Kokka 2010

Kokka F, Brockbank E, Oram D, Gallagher C, Bryant A. Hormonal therapy in advanced or recurrent endometrial cancer. *Cochrane Database of Systematic Reviews* 2010, Issue 12. [DOI: 10.1002/14651858.CD007926.pub2]

Miller 1981

Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. *Cancer* 1981;**47**:207-14.

Morris 1996

Morris M, Alvarez RD, Kinney WK, Wilson TO. Treatment of recurrent adenocarcinoma of the endometrium with pelvic exenteration. *Gynecologic Oncology* 1996;**60**:288.

Parmar 1998

Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. *Statistics in Medicine* 1998;**17**:2815-34.

Tierney 2007

Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. *Trials* 2007;**8**:16.

Yusuf 1985

Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. *Progress in Cardiovascular Diseases* 1985;**27**(5):335-71.

References to other published versions of this review

Humber 2005

Humber CE, Tierney J, Symonds PR, Collingwood M, Kirwan JJ, Williams C, et al. Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma. *Cochrane Database of Systematic Reviews* 2005, Issue 4. [DOI: 10.1002/14651858.CD003175.pub2]

Humber 2007

Humber CE, Tierney JF, Symonds RP, Collingwood M, Kirwan J, Williams C, et al. Chemotherapy for advanced, recurrent or metastatic endometrial cancer: a systematic review of Cochrane collaboration. *Annals of Oncology* 2007;**18**(3):409-20.

* Indicates the major publication for the study

CHARACTERISTICS OF STUDIES

Characteristics of included studies *[ordered by study ID]*

Aapro 2003

Methods	Randomised Phase II/III trial 1988 to 1994
Participants	177 women with histologically confirmed advanced or recurrent adenocarcinoma of the endometrium not thought to be suitable for radiotherapy or endocrine therapy. No prior chemotherapy, radiotherapy or hormone therapy in previous 4 weeks. WHO performance status ≤2
Interventions	Arm 1: doxorubicin 60 mg/m^2 IV every 28 days Arm 2: doxorubicin 60 mg/m^2 IV, cisplatin 50 mg/m^2 IV every 28 days
Outcomes	OS Progression-free interval Response Acute toxicity (WHO)
Notes	-

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	"During randomisation, patients were stratified according to institute, differentiation, type of disease and performance status using the minimisation technique"
Allocation concealment (selection bias)	Unclear risk	Not stated
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Participants and personnel were not blinded
Blinding of outcome assessment (detection bias)	Low risk	Assessment not blinded, but for primary outcome of OS, unlikely to introduce bias

Aapro 2003 *(Continued)*

All outcomes

Incomplete outcome data (attrition bias) All outcomes	Low risk	12 ineligible patients (7% of total randomised). Balanced by treatment arm. However, all patients were included in the analyses of efficacy
Selective reporting (reporting bias)	Low risk	No protocol available, but all outcomes of interest to review reported. Note: trial reports that PFS will be analysed; however, progression-free interval is reported

Cohen 1984

Methods	Prospective randomised trial 1977 to 1979
Participants	295 women with primary stage III, stage IV or recurrent or residual endometrial adenocarcinoma incurable by radiotherapy or surgery. No prior chemotherapy
Interventions	Arm 1: melphalan (7 mg/m²/day PO) plus 5-FU (525 mg/m²/day IV) for 4 days, every 28 days, plus megace (180 mg/day PO), daily for 8 weeks Arm 2: doxorubicin (40 mg/m² IV bolus), cyclophosphamide (400 mg/m² IV bolus), 5-FU (400 mg/m² IV bolus) every 21 days, plus megace (180 mg/day orally) daily for 8 weeks
Outcomes	OS Progression-free interval Response Acute toxicity (GOG)
Notes	63 patients assigned non-randomly to arm 1 and analysed separately

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	"Randomised... stratified on the basis of performance status, previous progestational therapy, measurable disease and stage"
Allocation concealment (selection bias)	Unclear risk	Not stated
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Participants and personnel were not blinded
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Assessment not blinded, but for primary outcome of OS, unlikely to introduce bias
Incomplete outcome data (attrition bias) All outcomes	High risk	38 patients excluded (13% of total randomised) from the analysis. Exclusions balanced by treatment arm. Main reason in both arms was errors either in pathology or administration

---

Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma (Review)

Cohen 1984 *(Continued)*

Selective reporting (reporting bias)	Low risk	No protocol available; however, trial reports all outcomes of interest to the review (note: progression-free interval not PFS)

Edmonson 1987

Methods	Randomised Phase II study 1980 to 1983
Participants	30 women with histologically confirmed, objectively evaluable endometrial carcinoma, refractory to progestin treatment. No prior chemotherapy. ECOG performance status ≤ 3
Interventions	Arm 1: cisplatin (60 mg/m^2) IV every 21 days until progression Arm 2: cisplatin (40 mg/m^2) IV, cyclophosphamide (400 mg/m^2) IV, doxorubicin (40 mg/m^2) IV every 28 days until progression
Outcomes	OS PFS Response Acute toxicity (NCI CTC v1)
Notes	No excluded patients

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	"assigned at random" and "stratified by PS [performance status], histology and stage"
Allocation concealment (selection bias)	Unclear risk	Not stated
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Participants and personnel were not blinded
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Assessment not blinded, but for primary outcome of OS, unlikely to introduce bias
Incomplete outcome data (attrition bias) All outcomes	Low risk	All patients included in analyses supplied by investigator for use in this review
Selective reporting (reporting bias)	Low risk	Insufficient detail in trial report, but all outcomes of interest were supplied by the investigator

Fleming 2004a

Methods	Randomised Phase III trial

Fleming 2004a *(Continued)*

	1998 to 2000
Participants	273 women with advance or recurrent endometrial cancer. No prior chemotherapy
Interventions	Arm 1: doxorubicin (60 mg/m^2) IV, cisplatin (50 mg/m^2) IV every 21 days for 7 cycles Arm 2: doxorubicin (45 mg/m^2) IV, cisplatin (50 mg/m^2) IV, paclitaxel (160 mg/m^2) IV every 21 days for 7 cycles plus G-CSF support
Outcomes	OS PFS Response Acute toxicity (NCI-CTC v2)
Notes	-

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	"Randomly assigned with equal probability of assignment to each treatment arm"
Allocation concealment (selection bias)	Low risk	Central telephone randomisation - sequence concealed from institutes and patients
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Participants and personnel were not blinded
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Assessment not blinded, but for primary outcome of OS, unlikely to introduce bias
Incomplete outcome data (attrition bias) All outcomes	Low risk	10 ineligible patients (4% or total randomised) excluded from the analyses, slightly imbalanced by arm but low numbers overall (7 vs 3)
Selective reporting (reporting bias)	Low risk	No protocol available but trial reports all outcomes of interest to the review (response, PFS and OS)

Fleming 2004b

Methods	Randomised Phase III trial 1996 to 1998
Participants	328 patients with primary stage III, stage IV or recurrent endometrial carcinoma. Prior hormone therapy permitted, but no prior chemotherapy. GOG performance status 0 to 2
Interventions	Arm 1: doxorubicin (60 mg/m^2) IV, cisplatin (50 mg/m^2) IV every 21 days for 7 cycles (max) or until progression or unacceptable toxicity Arm 2: doxorubicin (50 mg/m^2) IV, paclitaxel (150 mg/m^2) IV, filigastrim (5 µg/kg) day 3 to day 12 every 21 days for 7 cycles (max) or until progression or unacceptable toxicity

Fleming 2004b *(Continued)*

Outcomes	OS
	PFS
	Response Acute toxicity (GOG)
Notes	-

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	"Randomisation with equal probabilities balancing the sequence of assigned regimens within institutes and strata"
Allocation concealment (selection bias)	Low risk	Central allocation, with concealment of the treatment sequence
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Participants and personnel were not blinded
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Assessment not blinded, but for primary outcome of OS, unlikely to introduce bias
Incomplete outcome data (attrition bias) All outcomes	Low risk	11 ineligible patients (3% of total randomised) were excluded from the analyses. Slightly imbalance by arm (3 vs 8) but low numbers overall
Selective reporting (reporting bias)	Low risk	No protocol available but trial reports all outcomes of interest to the review (response, PFS and OS)

Gallion 2003

Methods	Randomised Phase III trial 1993 to 1996
Participants	352 women with histologically documented; primary stage II, IV or recurrent endometrial carcinoma. Prior hormonal therapy or biological response modifiers permitted, but had not received prior cytotoxic chemotherapy, more than 1 biological therapy or prior radiotherapy in previous 3 months
Interventions	Arm 1: (standard time) doxorubicin (60 mg/m^2) IV, cisplatin (60 mg/m^2) IV every 21 days for 8 cycles Arm 2: (circadian time) doxorubicin (60 mg/m^2) IV at 6 a.m., cisplatin (60 mg/m^2) IV at 6 p.m. every 21 days for 8 cycles
Outcomes	OS
	PFS
	Response Acute toxicity (GOG)
Notes	-

Gallion 2003 *(Continued)*

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Permuted block design: computerised random number generator with a block length of 4 assignments
Allocation concealment (selection bias)	Low risk	Central telephone randomisation. Sequence of treatment assignments was concealed
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Participants and personnel were not blinded
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Assessment not blinded, but for primary outcome of OS, unlikely to introduce bias
Incomplete outcome data (attrition bias) All outcomes	Low risk	10 ineligible patients (3% of the total randomised) excluded from the analyses, balanced by arm 1
Selective reporting (reporting bias)	Low risk	No protocol available but trial reports all outcomes of interest to the review (response, PFS and OS)

Horton 1978

Methods	Randomised Phase III trial 1974 to ?
Participants	47 women with histologically confirmed endometrial carcinoma with local extension or metastasis not amenable to cure and failed prior progestational therapy. No prior chemotherapy
Interventions	Arm 1: cyclophosphamide (666 mg/m^2) IV bolus every 21 days until progression Arm 2: doxorubicin (50 mg/m^2) IV bolus every 21 days until max dose of 550 mg/m^2 or progression
Outcomes	Survival Response Acute toxicity
Notes	Insufficient outcome data available to include this trial in the analyses

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Not stated
Allocation concealment (selection bias)	Low risk	Central office

---

Chemotherapy for advanced, recurrent or metastatic endometrial carcinoma (Review)

Copyright © 2015 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

Horton 1978 *(Continued)*

Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Participants and personnel were not blinded
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Assessment not blinded, but for primary outcome of OS, unlikely to introduce bias
Incomplete outcome data (attrition bias) All outcomes	High risk	7 patients (15%) were randomised but were excluded from the analysis for reasons of ineligibility (n = 3) or because no data were available (n = 4). It is unclear whether they received treatment
Selective reporting (reporting bias)	High risk	No protocol available. Trial reports median survival according to performance status only. OS and PFS not reported. Toxicity and response are reported. No data available from the trial investigators

Horton 1982

Methods	Randomised trial 1977 to 1979
Participants	131 women with histologically confirmed stage III or IV recurrent or metastatic adenocarcinoma, not amenable to standard surgery or RT. Prior progestational treatment allowed
Interventions	Arm 1: megestrol (3 x 80 mg/day PO); cyclophosphamide (400 mg/m^2) and doxorubicin (40 mg/m^2) IV bolus every 28 days Arm 2: megestrol (3 x 80 mg/day PO), cyclophosphamide (250 mg/m^2) and doxorubicin (30 mg/m^2) once, and 5-FU 300 mg/m^2 daily for 3 days (IV bolus) every 28 days
Outcomes	OS PFS Response Acute toxicity (ECOG scale)
Notes	

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	"Randomly permuted blocks, within strata, balanced by institution"
Allocation concealment (selection bias)	Unclear risk	Not stated
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Participants and personnel were not blinded

Horton 1982 *(Continued)*

Blinding of outcome assessment (detection bias) All outcomes	Low risk	Assessment not blinded, but for primary outcome of OS, unlikely to introduce bias
Incomplete outcome data (attrition bias) All outcomes	Low risk	No patients excluded from the analyses supplied for use in this review
Selective reporting (reporting bias)	Low risk	Paper reports detail insufficient for inclusion in analyses; however, investigator supplied all outcomes on request

Long 2006

Methods	Randomised prospective trial
	1992 to 1993
Participants	28 women with advanced, recurrent or metastatic endometrial carcinoma
Interventions	Arm 1: doxorubicin (30 mg/m^2), cisplatin (70 mg/m^2) IV every 28 days for max 4 cycles
	Arm 2: methotrexate (30 mg/m^2) IV, vinblastine (3 mg/m^2) IV days 1, 15 and 22, plus doxorubicin (30 mg/m^2) and cisplatin (70 mg/m^2) day 2, every 28 days for max 4 cycles
Outcomes	Survival
	Progression-free interval
	Response
	Toxicity (NCI-CTC, v1)
Notes	"Due to slow accrual and termination of the Gynecological Program in the NCCTG, this trial was closed prior to completion of its accrual objectives."

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Dynamic balancing
Allocation concealment (selection bias)	Unclear risk	Not stated
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Participants and personnel were not blinded
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Assessment not blinded, but for primary outcome of OS, unlikely to introduce bias
Incomplete outcome data (attrition bias)	Low risk	No patients excluded from analyses supplied by investigator for use in this review

Long 2006 *(Continued)*

All outcomes

Selective reporting (reporting bias)	Low risk	Trial reports response, PFS, OS and toxicity. Full details for all outcomes supplied by the investigator for use in this review

---

Nomura 2010a

Methods	Randomised Phase II trial
	2003 to 2005

Participants	90 women* with advanced, metastatic or recurrent endometrial carcinoma

Interventions	Arm 1: docetaxel (70 mg/m^2) IV and carboplatin (AUC = 6) every 21 days
	Arm 2: docetaxel (70 mg/m^2) IV and cisplatin (60 mg/m^2) IV every 21 days
	All regimen to be given until progression or adverse advents prohibit further treatment

Outcomes	OS
	PFS
	Response
	Acute toxicity (NCI-CTC, v2)

Notes	2 arms of a 3-arm study with Nomura 2010b. *90 women randomised across all 3 arms, 30 per arm

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Minimisation, stratified by prior taxane therapy and measurable lesions
Allocation concealment (selection bias)	Unclear risk	Not stated
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Participants and personnel were not blinded
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Assessment not blinded, but for primary outcome of OS, unlikely to introduce bias
Incomplete outcome data (attrition bias) All outcomes	Low risk	2 patients (3% of total randomised) were excluded after randomisation and were not included in the analyses
Selective reporting (reporting bias)	Low risk	Trial reports response, adverse events, treatment completion rate and PFS only. OS and PFS supplied by authors upon request to enable analysis as two separate treatment comparisons within this review

---

Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

Nomura 2010b

Methods	Randomised Phase II trial
	2003 to 2005
Participants	90 women* with advanced, metastatic or recurrent endometrial carcinoma
Interventions	Arm 2: docetaxel (70 mg/m^2) IV and cisplatin (60 mg/m^2) IV every 21 days
	Arm 3: paclitaxel 180 mg/m^2 and carboplatin (AUC = 6) IV on day 1, every 21 days
	All regimen to be given until progression or adverse advents prohibit further treatment
Outcomes	OS
	PFS
	Response
	Acute toxicity (NCI-CTC, v2)
Notes	2 arms of a 3-arm study with Nomura 2010a. *90 women randomised across all 3 arms, 30 per arm

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Low risk	Minimisation, stratified by prior taxane therapy and measurable lesions
Allocation concealment (selection bias)	Unclear risk	Not stated
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Participants and personnel were not blinded
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Assessment not blinded, but for primary outcome of OS, unlikely to introduce bias
Incomplete outcome data (attrition bias) All outcomes	Low risk	1 patient (2% of total randomised) was excluded after randomisation and were not included in the analyses
Selective reporting (reporting bias)	Low risk	Trial reports response, adverse events, treatment completion rate and PFS only. OS and PFS supplied by authors upon request to enable analysis as two separate treatment comparisons within this review

Pawinski 1999

Methods	Randomised Phase II study
	1987 to 1994

Pawinski 1999 *(Continued)*

Participants	74 women with recurrent or metastatic histologically confirmed endometrial carcinoma. Prior chemotherapy permitted, but not the study drugs
Interventions	Arm 1: ifosfamide (5 g/m^2) IV every 21 days until progression
	Arm 2: cyclophosphamide (1200 mg/m^2) IV every 21 days until progression
Outcomes	OS
	Progression-free interval
	Response rate Acute toxicity (GOG)
Notes	-

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	"Randomly given"
Allocation concealment (selection bias)	Unclear risk	Not stated
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Participants and personnel were not blinded
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Assessment not blinded, but for primary outcome of OS, unlikely to introduce bias
Incomplete outcome data (attrition bias) All outcomes	Low risk	13 patients (18% of the total randomised) were excluded from the analysis for reasons of ineligibility. It is unclear whether they received treatment; however, full ITT analyses were provided by investigators for this review
Selective reporting (reporting bias)	Low risk	Trial reports response rates and toxicity. Deaths and progressions were collected but not reported; however, survival and PFSl results were provided by the investigators upon request for use in this review

Thigpen 1994

Methods	Randomised Phase III trial 1979 to 1985
Participants	387 women with histologically documented advanced or recurrent endometrial adenocarcinoma, adenoacanthoma or adenosquamous carcinoma no longer amenable to control with surgery or radiotherapy; no prior chemotherapy
Interventions	Arm 1: doxorubicin (60 mg/m^2) IV every 21 days for 8 cycles Arm 2: doxorubicin (60 mg/m^2) IV, cyclophosphamide (500 mg/m^2) IV every 21 days for 8 cycles
Outcomes	OS

Thigpen 1994 *(Continued)*

	Progression-free interval
	Response Acute toxicity (GOG)
Notes	-

Risk of bias

Bias	Authors' judgement	Support for judgement
Random sequence genera- tion (selection bias)	Unclear risk	"Randomly allocated"
Allocation concealment (selection bias)	Unclear risk	Not stated
Blinding of participants and personnel (perfor- mance bias) All outcomes	Unclear risk	Participants and personnel were not blinded
Blinding of outcome as- sessment (detection bias) All outcomes	Low risk	Assessment not blinded, but for primary outcome of OS, unlikely to introduce bias
Incomplete outcome data (attrition bias) All outcomes	Low risk	31 patients (8% of the total randomised) were excluded from the analysis for reasons of ineligibility. 15 were excluded prior to treatment (8 from arm 1 and 15 from arm 2); 16 were treated and subsequently excluded from the analysis
Selective reporting (re- porting bias)	Low risk	No protocol available but trial reports all outcomes of interest to the review (note: progression-free interval reported and not PFS)

Thigpen 2004

Methods	Randomised Phase III trial 1988 to 1992
Participants	299 women with advanced or recurrent endometrial carcinoma, no prior chemotherapy
Interventions	Arm 1: doxorubicin (60 mg/m^2) IV every 21 days for 8 cycles Arm 2: doxorubicin (60 mg/m^2) IV, cisplatin (50 mg/m^2) IV every 21 days for 8 cycles
Outcomes	Survival PFS Response Acute toxicity (GOG)
Notes	-

Risk of bias

Bias	Authors' judgement	Support for judgement

Thigpen 2004 *(Continued)*

Random sequence generation (selection bias)	Low risk	"Sequentially drawn from pre-allocated lists of treatments, randomly permuted and balanced within blocks"
Allocation concealment (selection bias)	Low risk	"All patients were registered centrally. The randomised treatment was not revealed until registration was complete"
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Participants and personnel were not blinded
Blinding of outcome assessment (detection bias) All outcomes	Low risk	Assessment not blinded, but for primary outcome of OS, unlikely to introduce bias
Incomplete outcome data (attrition bias) All outcomes	Low risk	18 ineligible patients were randomised but excluded from the analyses (6% of the total randomised). Also, 3 not receiving the study agent excluded from the toxicity analysis
Selective reporting (reporting bias)	Low risk	Protocol not available but trial reports all outcomes of interest to the review

---

Weber 2003

Methods	Randomised Phase II trial
	1997 to 2002
Participants	70 women with recurrent or advanced endometrial carcinoma
Interventions	Arm 1: doxorubicin (60 mg/m^2) and cisplatin (50 mg/m^2) every 21 days for 6 cycles
	Arm 2: carboplatin (AUC = 5) and paclitaxel (175 mg/m^2) every 21 days for 6 cycles
Outcomes	OS
	PFS
	Response
	Acute Toxicity
Notes	Insufficient outcome data available to include this trial in the analyses

Risk of bias

Bias	**Authors' judgement**	**Support for judgement**
Random sequence generation (selection bias)	Unclear risk	"Patients were randomised"
Allocation concealment (selection bias)	Unclear risk	Not stated
Blinding of participants and personnel (performance bias)	Unclear risk	Participants and personnel were not blinded

---

Weber 2003 *(Continued)*

All outcomes

Blinding of outcome assessment (detection bias) All outcomes	Low risk	Assessment not blinded, but for primary outcome of OS, unlikely to introduce bias
Incomplete outcome data (attrition bias) All outcomes	Low risk	No patients excluded from analysis
Selective reporting (reporting bias)	High risk	No protocol available. Reported as an abstract only with insufficient detail for inclusion in review

5-FU: 5-fluorouracil; AUC: area under curve; ECOG: Eastern Cooperative Oncology Group; G-CSF: granulocyte colony-stimulating factor; GOG: Gynecologic Oncology Group; ITT: intention to treat; IV: intravenous; max: maximum; NCCTG: North Central Cancer Treatment Group; NCI CTC: National Cancer Institute Common Toxicity Criteria; OS: overall survival; PFS: progression-free survival; PO, orally; WHO: World Health Organization.

Characteristics of ongoing studies *[ordered by study ID]*

NCT00052312

Trial name or title	Doxorubicin and Cisplatin With or Without Paclitaxel in Treating Patients With Locally Advanced, Metastatic, and/or Relapsed Endometrial Cancer
Methods	Randomised Phase II trial
Participants	Patients With Locally Advanced, Metastatic, and/or Relapsed Endometrial Cancer
Interventions	Doxorubicin, paclitaxel and cisplatin versus doxorubicin and cisplatin
Outcomes	Progression free survival; overall survival and toxicity
Starting date	September 2002
Contact information	Nicholas S. Reed, MD University of Glasgow
Notes	

NCT00063999

Trial name or title	Combination Chemotherapy in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
Methods	Randomized Phase III Trial
Participants	Patients with stage III, stage IV, or recurrent endometrial cancer.
Interventions	Doxorubicin, cisplatin, paclitaxel and filgrastim (G-CSF) versus paclitaxel and carboplatin
Outcomes	Overall survival, Progression free survival
Starting date	August 2003

Contact information	Philip J. DiSaia, Gynecologic Oncology Group
Notes	

DATA AND ANALYSES

Comparison 1. More versus less chemotherapy

Outcome or subgroup title	No. of studies	No. of partici-pants	Statistical method	Effect size
1 Overall survival	8	1519	Hazard Ratio (Fixed, 95% CI)	0.86 [0.77, 0.96]
1.1 Cisplatin in combination versus cisplatin alone	1	30	Hazard Ratio (Fixed, 95% CI)	0.76 [0.36, 1.58]
1.2 Doxorubicin in combination versus doxorubicin alone	3	814	Hazard Ratio (Fixed, 95% CI)	0.89 [0.77, 1.03]
1.3 Doxorubicin + cisplatin plus other drugs versus doxorubicin + cisplatin	2	291	Hazard Ratio (Fixed, 95% CI)	0.75 [0.58, 0.97]
1.4 Other 3-drug combination versus other 2-drug combination	2	384	Hazard Ratio (Fixed, 95% CI)	0.88 [0.71, 1.08]
2 Progression-free survival	8	1526	Hazard Ratio (Fixed, 95% CI)	0.82 [0.74, 0.90]
2.1 Cisplatin in combination versus cisplatin alone	1	30	Hazard Ratio (Fixed, 95% CI)	0.85 [0.37, 1.92]
2.2 Doxorubicin in combination versus doxorubicin	3	821	Hazard Ratio (Fixed, 95% CI)	0.85 [0.74, 0.97]
2.3 Doxorubicin + cisplatin plus other drugs versus doxorubicin + cisplatin	2	291	Hazard Ratio (Fixed, 95% CI)	0.64 [0.49, 0.82]
2.4 Other 3-drug combination versus other 2-drug combination	2	384	Hazard Ratio (Fixed, 95% CI)	0.88 [0.72, 1.08]
3 Grade 3-4 nausea/vomiting	5	761	Peto Odds Ratio (Peto, Fixed, 95% CI)	2.64 [1.71, 4.09]
3.1 Cisplatin in combination versus cisplatin	1	30	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.84 [0.17, 4.13]
3.2 Doxorubicin in combination versus doxorubicin	2	443	Peto Odds Ratio (Peto, Fixed, 95% CI)	3.95 [2.27, 6.89]
3.3 Doxorubicin + cisplatin plus other drugs versus doxorubicin + cisplatin	2	288	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.56 [0.71, 3.42]
3.4 Other 3-drug combination versus other 2-drug combination	0	0	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.0 [0.0, 0.0]

Cochrane
Library

**Trusted evidence.
Informed decisions.
Better health.**

Cochrane Database of Systematic Reviews

Outcome or subgroup title	No. of studies	No. of partici-pants	Statistical method	Effect size
4 Grade 3-4 diarrhoea/other GI	6	873	Peto Odds Ratio (Peto, Fixed, 95% CI)	2.25 [1.09, 4.63]
4.1 Cisplatin in combination versus cis-platin	1	30	Peto Odds Ratio (Peto, Fixed, 95% CI)	6.52 [0.13, 331.51]
4.2 Doxorubicin in combination versus doxorubicin	2	443	Peto Odds Ratio (Peto, Fixed, 95% CI)	2.36 [0.83, 6.68]
4.3 Doxorubicin/cisplatin plus other drugs versus doxorubicin/cisplatin	2	288	Peto Odds Ratio (Peto, Fixed, 95% CI)	2.44 [0.84, 7.12]
4.4 Other 3-drug combination versus other 2-drug combinations	1	112	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.14 [0.00, 6.82]
5 Grade 3-4 white blood cell toxicity	7		Peto Odds Ratio (Peto, Fixed, 95% CI)	Subtotals only
5.1 Cisplatin in combination versus cis-platin	1	30	Peto Odds Ratio (Peto, Fixed, 95% CI)	3.28 [0.76, 14.19]
5.2 Doxorubicin in combination versus doxorubicin	2	443	Peto Odds Ratio (Peto, Fixed, 95% CI)	2.51 [1.73, 3.65]
5.3 Doxorubicin/cisplatin plus other drugs versus doxorubicin/cisplatin	2	288	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.45 [0.29, 0.72]
5.4 Other 3-drug combination versus other 2-drug combinations	2	397	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.51 [0.33, 0.78]
6 Grade 3-4 thrombocytopenia	6		Peto Odds Ratio (Peto, Fixed, 95% CI)	Subtotals only
6.1 Cisplatin in combination versus cis-platin	1	30	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.12 [0.00, 5.96]
6.2 Doxorubicin in combination versus doxorubicin	2	443	Peto Odds Ratio (Peto, Fixed, 95% CI)	4.12 [2.08, 8.14]
6.3 Doxorubicin/cisplatin plus other drugs versus doxorubicin/cisplatin	2	288	Peto Odds Ratio (Peto, Fixed, 95% CI)	5.65 [2.60, 12.28]
6.4 Other 3-drug combination versus other 2-drug combinations	1	266	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.12 [0.05, 0.29]
7 Grade 3-4 anaemia	4	596	Peto Odds Ratio (Peto, Fixed, 95% CI)	5.32 [2.62, 10.81]
7.1 Cisplatin in combination versus cis-platin	1	30	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.0 [0.0, 0.0]
7.2 Doxorubicin in combination versus doxorubicin	1	278	Peto Odds Ratio (Peto, Fixed, 95% CI)	5.32 [2.62, 10.81]
7.3 Doxorubicin/cisplatin plus other drugs versus doxorubicin/cisplatin	2	288	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.0 [0.0, 0.0]

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
7.4 Other 3-drug combination versus other 2-drug combinations	0	0	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.0 [0.0, 0.0]
8 Grade 3-4 alopecia	5	595	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.86 [1.01, 3.42]
8.1 Cisplatin in combination versus cisplatin	1	30	Peto Odds Ratio (Peto, Fixed, 95% CI)	10.63 [2.01, 56.35]
8.2 Doxorubicin in combination versus doxorubicin	1	165	Peto Odds Ratio (Peto, Fixed, 95% CI)	1.42 [0.74, 2.74]
8.3 Doxorubicin/cisplatin plus other drugs versus doxorubicin/cisplatin	2	288	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.0 [0.0, 0.0]
8.4 Other 3-drug combination versus other 2-drug combinations	1	112	Peto Odds Ratio (Peto, Fixed, 95% CI)	0.0 [0.0, 0.0]

Analysis 1.1. Comparison 1 More versus less chemotherapy, Outcome 1 Overall survival.

Study or subgroup	Experimental N	Control N	log[Hazard Ratio] (SE)	Hazard Ratio IV, Fixed, 95% CI	Weight	Hazard Ratio IV, Fixed, 95% CI
1.1.1 Cisplatin in combination versus cisplatin alone						
Edmonson 1987	16	14	-0.3 (0.375)		2.07%	0.76[0.36,1.58]
Subtotal (95% CI)					2.07%	**0.76[0.36,1.58]**
Heterogeneity: Not applicable						
Test for overall effect: Z=0.74(P=0.46)						
1.1.2 Doxorubicin in combination versus doxorubicin alone						
Thigpen 1994	185	171	-0.1 (0.108)		24.85%	0.93[0.75,1.15]
Aapro 2003	90	87	-0.3 (0.158)		11.64%	0.77[0.57,1.06]
Thigpen 2004	131	150	-0.1 (0.125)		18.74%	0.93[0.73,1.18]
Subtotal (95% CI)					55.23%	**0.89[0.77,1.03]**
Heterogeneity: Tau²=0; Chi²=1.01, df=2(P=0.6); I²=0%						
Test for overall effect: Z=1.56(P=0.12)						
1.1.3 Doxorubicin + cisplatin plus other drugs versus doxorubicin + cisplatin						
Fleming 2004a	134	129	-0.3 (0.141)		14.68%	0.75[0.57,0.99]
Long 2006	13	15	-0.3 (0.409)		1.74%	0.74[0.33,1.65]
Subtotal (95% CI)					16.41%	**0.75[0.58,0.97]**
Heterogeneity: Tau²=0; Chi²=0, df=1(P=0.98); I²=0%						
Test for overall effect: Z=2.17(P=0.03)						
1.1.4 Other 3-drug combination versus other 2-drug combination						
Horton 1982	67	64	-0.2 (0.179)		9.07%	0.81[0.57,1.15]
Cohen 1984	131	122	-0.1 (0.13)		17.21%	0.91[0.71,1.18]
Subtotal (95% CI)					26.28%	**0.88[0.71,1.08]**
Heterogeneity: Tau²=0; Chi²=0.29, df=1(P=0.59); I²=0%						
Test for overall effect: Z=1.26(P=0.21)						

Favours Experimental 0.2 0.5 1 2 5 Favours Control

Study or subgroup	Experi-mental	Control	log[Hazard Ratio]	Hazard Ratio	Weight	Hazard Ratio
	N	N	(SE)	IV, Fixed, 95% CI		IV, Fixed, 95% CI
Total (95% CI)				◆	100%	**0.86[0.77,0.96]**

Heterogeneity: Tau²=0; Chi²=2.79, df=7(P=0.9); I²=0%

Test for overall effect: Z=2.79(P=0.01)

Test for subgroup differences: Chi²=1.49, df=1 (P=0.69), I²=0%

Favours Experimental 0.2 0.5 1 2 5 Favours Control

Analysis 1.2. Comparison 1 More versus less chemotherapy, Outcome 2 Progression-free survival.

Study or subgroup	Experi-mental	Control	log[Hazard Ratio]	Hazard Ratio	Weight	Hazard Ratio
	N	N	(SE)	IV, Fixed, 95% CI		IV, Fixed, 95% CI
1.2.1 Cisplatin in combination versus cisplatin alone						
Edmonson 1987	16	14	-0.2 (0.418)		1.52%	0.85[0.37,1.92]
Subtotal (95% CI)				◆	1.52%	**0.85[0.37,1.92]**
Heterogeneity: Not applicable						
Test for overall effect: Z=0.4(P=0.69)						
1.2.2 Doxorubicin in combination versus doxorubicin						
Thigpen 1994	185	171	-0.1 (0.088)	■	33.99%	0.89[0.75,1.06]
Aapro 2003	89	95	-0 (0.2)		6.64%	0.95[0.64,1.41]
Thigpen 2004	131	150	-0.3 (0.124)		17.18%	0.74[0.58,0.94]
Subtotal (95% CI)				◆	57.81%	**0.85[0.74,0.97]**
Heterogeneity: Tau²=0; Chi²=1.97, df=2(P=0.37); I²=0%						
Test for overall effect: Z=2.42(P=0.02)						
1.2.3 Doxorubicin + cisplatin plus other drugs versus doxorubicin + cisplatin						
Fleming 2004a	134	129	-0.5 (0.135)		14.61%	0.6[0.46,0.78]
Long 2006	13	15	0 (0.396)		1.69%	1.04[0.48,2.26]
Subtotal (95% CI)				◆	16.29%	**0.64[0.49,0.82]**
Heterogeneity: Tau²=0; Chi²=1.72, df=1(P=0.19); I²=41.87%						
Test for overall effect: Z=3.56(P=0)						
1.2.4 Other 3-drug combination versus other 2-drug combination						
Horton 1982	67	64	-0.3 (0.191)		7.26%	0.76[0.52,1.11]
Cohen 1984	131	122	-0.1 (0.124)		17.13%	0.94[0.74,1.2]
Subtotal (95% CI)				◆	24.38%	**0.88[0.72,1.08]**
Heterogeneity: Tau²=0; Chi²=0.88, df=1(P=0.35); I²=0%						
Test for overall effect: Z=1.19(P=0.23)						
Total (95% CI)				◆	100%	**0.82[0.74,0.9]**

Heterogeneity: Tau²=0; Chi²=9.35, df=7(P=0.23); I²=25.12%

Test for overall effect: Z=3.91(P<0.0001)

Test for subgroup differences: Chi²=4.78, df=1 (P=0.19), I²=37.28%

Favours experimental 0.1 0.2 0.5 1 2 5 10 Favours control

Analysis 1.3. Comparison 1 More versus less chemotherapy, Outcome 3 Grade 3-4 nausea/vomiting.

Study or subgroup	Treatment n/N	Control n/N	Peto Odds Ratio Peto, Fixed, 95% CI	Weight	Peto Odds Ratio Peto, Fixed, 95% CI
1.3.1 Cisplatin in combination versus cisplatin					
Edmonson 1987	4/16	4/14		7.48%	0.84[0.17,4.13]
Subtotal (95% CI)	**16**	**14**		**7.48%**	**0.84[0.17,4.13]**
Total events: 4 (Treatment), 4 (Control)					
Heterogeneity: Not applicable					
Test for overall effect: Z=0.22(P=0.83)					
1.3.2 Doxorubicin in combination versus doxorubicin					
Aapro 2003	30/83	10/82		37.76%	3.66[1.8,7.43]
Thigpen 2004	17/129	4/149		24.01%	4.47[1.83,10.89]
Subtotal (95% CI)	**212**	**231**		**61.76%**	**3.95[2.27,6.89]**
Total events: 47 (Treatment), 14 (Control)					
Heterogeneity: Tau²=0; Chi²=0.12, df=1(P=0.73); I²=0%					
Test for overall effect: Z=4.85(P<0.0001)					
1.3.3 Doxorubicin + cisplatin plus other drugs versus doxorubicin + cisplatin					
Fleming 2004a	12/131	8/129		22.95%	1.51[0.61,3.76]
Long 2006	5/13	4/15		7.8%	1.68[0.35,8.03]
Subtotal (95% CI)	**144**	**144**		**30.75%**	**1.56[0.71,3.42]**
Total events: 17 (Treatment), 12 (Control)					
Heterogeneity: Tau²=0; Chi²=0.01, df=1(P=0.91); I²=0%					
Test for overall effect: Z=1.1(P=0.27)					
1.3.4 Other 3-drug combination versus other 2-drug combination					
Subtotal (95% CI)	**0**	**0**			**Not estimable**
Total events: 0 (Treatment), 0 (Control)					
Heterogeneity: Not applicable					
Test for overall effect: Not applicable					
Total (95% CI)	**372**	**389**		**100%**	**2.64[1.71,4.09]**
Total events: 68 (Treatment), 30 (Control)					
Heterogeneity: Tau²=0; Chi²=5.89, df=4(P=0.21); I²=32.05%					
Test for overall effect: Z=4.37(P<0.0001)					
Test for subgroup differences: Chi²=5.75, df=1 (P=0.06), I²=65.24%					

Favours treatment 0.1 0.2 0.5 1 2 5 10 Favours control

Analysis 1.4. Comparison 1 More versus less chemotherapy, Outcome 4 Grade 3-4 diarrhoea/other GI.

Study or subgroup	Treatment n/N	Control n/N	Peto Odds Ratio Peto, Fixed, 95% CI	Weight	Peto Odds Ratio Peto, Fixed, 95% CI
1.4.1 Cisplatin in combination versus cisplatin					
Edmonson 1987	1/16	0/14		3.37%	6.52[0.13,331.51]
Subtotal (95% CI)	**16**	**14**		**3.37%**	**6.52[0.13,331.51]**
Total events: 1 (Treatment), 0 (Control)					
Heterogeneity: Not applicable					
Test for overall effect: Z=0.94(P=0.35)					

Favours treatment 0.01 0.1 1 10 100 Favours control

Study or subgroup	Treatment	Control	Peto Odds Ratio	Weight	Peto Odds Ratio
	n/N	n/N	Peto, Fixed, 95% CI		Peto, Fixed, 95% CI
1.4.2 Doxorubicin in combination versus doxorubicin					
Aapro 2003	0/83	0/82			Not estimable
Thigpen 2004	10/129	5/149		47.94%	2.36[0.83,6.68]
Subtotal (95% CI)	212	231		47.94%	2.36[0.83,6.68]
Total events: 10 (Treatment), 5 (Control)					
Heterogeneity: Not applicable					
Test for overall effect: Z=1.62(P=0.11)					
1.4.3 Doxorubicin/cisplatin plus other drugs versus doxorubicin/cis-platin					
Fleming 2004a	9/131	4/129		41.94%	2.2[0.72,6.71]
Long 2006	1/13	0/15		3.37%	8.62[0.17,438.7]
Subtotal (95% CI)	144	144		45.31%	2.44[0.84,7.12]
Total events: 10 (Treatment), 4 (Control)					
Heterogeneity: Tau²=0; Chi²=0.43, df=1(P=0.51); I²=0%					
Test for overall effect: Z=1.63(P=0.1)					
1.4.4 Other 3-drug combination versus other 2-drug combinations					
Horton 1982	0/56	1/56		3.38%	0.14[0,6.82]
Subtotal (95% CI)	56	56		3.38%	0.14[0,6.82]
Total events: 0 (Treatment), 1 (Control)					
Heterogeneity: Not applicable					
Test for overall effect: Z=1(P=0.32)					
Total (95% CI)	428	445		100%	2.25[1.09,4.63]
Total events: 21 (Treatment), 10 (Control)					
Heterogeneity: Tau²=0; Chi²=2.71, df=4(P=0.61); I²=0%					
Test for overall effect: Z=2.2(P=0.03)					
Test for subgroup differences: Chi²=2.29, df=1 (P=0.52), I²=0%					

Favours treatment 0.01 0.1 1 10 100 Favours control

Analysis 1.5. Comparison 1 More versus less chemotherapy, Outcome 5 Grade 3-4 white blood cell toxicity.

Study or subgroup	Treatment	Control	Peto Odds Ratio	Weight	Peto Odds Ratio
	n/N	n/N	Peto, Fixed, 95% CI		Peto, Fixed, 95% CI
1.5.1 Cisplatin in combination versus cisplatin					
Edmonson 1987	8/16	3/14		100%	3.28[0.76,14.19]
Subtotal (95% CI)	16	14		100%	3.28[0.76,14.19]
Total events: 8 (Treatment), 3 (Control)					
Heterogeneity: Not applicable					
Test for overall effect: Z=1.59(P=0.11)					
1.5.2 Doxorubicin in combination versus doxorubicin					
Aapro 2003	46/83	25/82		36.97%	2.75[1.49,5.08]
Thigpen 2004	80/129	60/149		63.03%	2.38[1.49,3.81]
Subtotal (95% CI)	212	231		100%	2.51[1.73,3.65]
Total events: 126 (Treatment), 85 (Control)					
Heterogeneity: Tau²=0; Chi²=0.13, df=1(P=0.72); I²=0%					
Test for overall effect: Z=4.83(P<0.0001)					

Favours treatment 0.1 0.2 0.5 1 2 5 10 Favours control

Study or subgroup	Treatment	Control	Peto Odds Ratio	Weight	Peto Odds Ratio
	n/N	n/N	Peto, Fixed, 95% CI		Peto, Fixed, 95% CI

1.5.3 Doxorubicin/cisplatin plus other drugs versus doxorubicin/cisplatin

Fleming 2004a	59/131	89/129		90.05%	0.38[0.23,0.62]
Long 2006	9/13	7/15		9.95%	2.43[0.56,10.61]
Subtotal (95% CI)	**144**	**144**		**100%**	**0.45[0.29,0.72]**

Total events: 68 (Treatment), 96 (Control)

Heterogeneity: Tau²=0; Chi²=5.52, df=1(P=0.02); I²=81.88%

Test for overall effect: Z=3.32(P=0)

1.5.4 Other 3-drug combination versus other 2-drug combinations

Cohen 1984	37/131	60/135		71.33%	0.5[0.3,0.82]
Horton 1982	13/67	20/64		28.67%	0.54[0.24,1.18]
Subtotal (95% CI)	**198**	**199**		**100%**	**0.51[0.33,0.78]**

Total events: 50 (Treatment), 80 (Control)

Heterogeneity: Tau²=0; Chi²=0.02, df=1(P=0.88); I²=0%

Test for overall effect: Z=3.15(P=0)

Test for subgroup differences: Chi²=46.74, df=1 (P<0.0001), I²=93.58%

Favours treatment 0.1 0.2 0.5 1 2 5 10 Favours control

Analysis 1.6. Comparison 1 More versus less chemotherapy, Outcome 6 Grade 3-4 thrombocytopenia.

Study or subgroup	Treatment	Control	Peto Odds Ratio	Weight	Peto Odds Ratio
	n/N	n/N	Peto, Fixed, 95% CI		Peto, Fixed, 95% CI

1.6.1 Cisplatin in combination versus cisplatin

| Edmonson 1987 | 0/16 | 1/14 | | 100% | 0.12[0,5.96] |
| **Subtotal (95% CI)** | **16** | **14** | | **100%** | **0.12[0,5.96]** |

Total events: 0 (Treatment), 1 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=1.07(P=0.29)

1.6.2 Doxorubicin in combination versus doxorubicin

Aapro 2003	11/83	4/82		41.44%	2.74[0.95,7.89]
Thigpen 2004	18/129	3/149		58.56%	5.49[2.26,13.38]
Subtotal (95% CI)	**212**	**231**		**100%**	**4.12[2.08,8.14]**

Total events: 29 (Treatment), 7 (Control)

Heterogeneity: Tau²=0; Chi²=0.97, df=1(P=0.32); I²=0%

Test for overall effect: Z=4.07(P<0.0001)

1.6.3 Doxorubicin/cisplatin plus other drugs versus doxorubicin/cisplatin

Fleming 2004a	22/131	3/129		89.14%	5.25[2.31,11.96]
Long 2006	3/13	0/15		10.86%	10.24[0.97,108.22]
Subtotal (95% CI)	**144**	**144**		**100%**	**5.65[2.6,12.28]**

Total events: 25 (Treatment), 3 (Control)

Heterogeneity: Tau²=0; Chi²=0.27, df=1(P=0.6); I²=0%

Test for overall effect: Z=4.37(P<0.0001)

1.6.4 Other 3-drug combination versus other 2-drug combinations

| Cohen 1984 | 0/131 | 21/135 | | 100% | 0.12[0.05,0.29] |

Favours treatment 0.1 0.2 0.5 1 2 5 10 Favours control

Study or subgroup	Treatment n/N	Control n/N	Peto Odds Ratio Peto, Fixed, 95% CI	Weight	Peto Odds Ratio Peto, Fixed, 95% CI
Subtotal (95% CI)	131	135		100%	0.12[0.05,0.29]

Total events: 0 (Treatment), 21 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=4.69(P<0.0001)

Test for subgroup differences: Chi²=51.7, df=1 (P<0.0001), I²=94.2%

Favours treatment 0.1 0.2 0.5 1 2 5 10 Favours control

Analysis 1.7. Comparison 1 More versus less chemotherapy, Outcome 7 Grade 3-4 anaemia.

Study or subgroup	Treatment n/N	Control n/N	Peto Odds Ratio Peto, Fixed, 95% CI	Weight	Peto Odds Ratio Peto, Fixed, 95% CI
1.7.1 Cisplatin in combination versus cisplatin					
Edmonson 1987	0/16	0/14			Not estimable
Subtotal (95% CI)	16	14			Not estimable

Total events: 0 (Treatment), 0 (Control)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

1.7.2 Doxorubicin in combination versus doxorubicin					
Thigpen 2004	29/129	6/149		100%	5.32[2.62,10.81]
Subtotal (95% CI)	129	149		100%	5.32[2.62,10.81]

Total events: 29 (Treatment), 6 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=4.62(P<0.0001)

1.7.3 Doxorubicin/cisplatin plus other drugs versus doxorubicin/cisplatin					
Long 2006	0/13	0/15			Not estimable
Fleming 2004a	0/131	0/129			Not estimable
Subtotal (95% CI)	144	144			Not estimable

Total events: 0 (Treatment), 0 (Control)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

1.7.4 Other 3-drug combination versus other 2-drug combinations					
Subtotal (95% CI)	0	0			Not estimable

Total events: 0 (Treatment), 0 (Control)

Heterogeneity: Not applicable

Test for overall effect: Not applicable

Total (95% CI)	289	307		100%	5.32[2.62,10.81]

Total events: 29 (Treatment), 6 (Control)

Heterogeneity: Not applicable

Test for overall effect: Z=4.62(P<0.0001)

Test for subgroup differences: Not applicable

Favours treatment 0.1 0.2 0.5 1 2 5 10 Favours control

## Analysis 1.8.   Comparison 1 More versus less chemotherapy, Outcome 8 Grade 3-4 alopecia.

Study or subgroup	Treatment n/N	Control n/N	Peto Odds Ratio Peto, Fixed, 95% CI	Weight	Peto Odds Ratio Peto, Fixed, 95% CI
1.8.1 Cisplatin in combination versus cisplatin					
Edmonson 1987	7/16	0/14		13.36%	10.63[2.01,56.35]
Subtotal (95% CI)	**16**	**14**		**13.36%**	**10.63[2.01,56.35]**
Total events: 7 (Treatment), 0 (Control)					
Heterogeneity: Not applicable					
Test for overall effect: Z=2.78(P=0.01)					
1.8.2 Doxorubicin in combination versus doxorubicin					
Aapro 2003	60/83	53/82		86.64%	1.42[0.74,2.74]
Subtotal (95% CI)	**83**	**82**		**86.64%**	**1.42[0.74,2.74]**
Total events: 60 (Treatment), 53 (Control)					
Heterogeneity: Not applicable					
Test for overall effect: Z=1.06(P=0.29)					
1.8.3 Doxorubicin/cisplatin plus other drugs versus doxorubicin/cisplatin					
Long 2006	0/13	0/15			Not estimable
Fleming 2004a	0/131	0/129			Not estimable
Subtotal (95% CI)	**144**	**144**			**Not estimable**
Total events: 0 (Treatment), 0 (Control)					
Heterogeneity: Not applicable					
Test for overall effect: Not applicable					
1.8.4 Other 3-drug combination versus other 2-drug combinations					
Horton 1982	0/56	0/56			Not estimable
Subtotal (95% CI)	**56**	**56**			**Not estimable**
Total events: 0 (Treatment), 0 (Control)					
Heterogeneity: Not applicable					
Test for overall effect: Not applicable					
Total (95% CI)	**299**	**296**		**100%**	**1.86[1.01,3.42]**
Total events: 67 (Treatment), 53 (Control)					
Heterogeneity: Tau²=0; Chi²=4.84, df=1(P=0.03); I²=79.36%					
Test for overall effect: Z=2(P=0.05)					
Test for subgroup differences: Chi²=4.84, df=1 (P=0.03), I²=79.36%					

Favours treatment 0.02 0.1 1 10 50 Favours control

Comparison 2.   Chemotherapy doublet versus chemotherapy doublet

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
1 Survival	4		Hazard Ratio (Fixed, 95% CI)	Subtotals only
1.1 Doxorubicin + cisplatin (circadian timed) versus doxorubicin + cisplatin (standard timed)	1	342	Hazard Ratio (Fixed, 95% CI)	1.07 [0.86, 1.34]
1.2 Doxorubicin + paclitaxel (plus filgrastin) versus doxorubicin + cisplatin	1	317	Hazard Ratio (Fixed, 95% CI)	1.0 [0.78, 1.28]

Outcome or subgroup title	No. of studies	No. of partici-pants	Statistical method	Effect size
1.3 Docetaxel + cisplatin versus docetaxel + carbo-platin	1	59	Hazard Ratio (Fixed, 95% CI)	0.63 [0.28, 1.42]
1.4 Paclitaxel + carboplatin versus docetaxel + carboplatin	1	58	Hazard Ratio (Fixed, 95% CI)	1.00 [0.48, 2.11]
2 Progression-free survival	4		Hazard Ratio (Fixed, 95% CI)	Subtotals only
2.1 Doxorubicin+ cisplatin (circadian timed) ver-sus doxorubicin/cisplatin (standard timed)	1	342	Hazard Ratio (Fixed, 95% CI)	1.06 [0.85, 1.32]
2.2 Doxorubicin + paclitaxel (with filgrastin) ver-sus doxorubicin + cisplatin	1	317	Hazard Ratio (Fixed, 95% CI)	1.01 [0.80, 1.28]
2.3 Docetaxel + cisplatin versus docetaxel + carbo-platin	1	58	Hazard Ratio (Fixed, 95% CI)	0.83 [0.46, 1.49]
2.4 Paclitaxel + carboplatin versus docetaxel + carboplatin	1	59	Hazard Ratio (Fixed, 95% CI)	0.90 [0.49, 1.67]

Analysis 2.1. Comparison 2 Chemotherapy doublet versus chemotherapy doublet, Outcome 1 Survival.

Study or subgroup	Experi-mental	Control	log[Hazard Ratio]	Hazard Ratio	Weight	Hazard Ratio
	N	N	(SE)	IV, Fixed, 95% CI		IV, Fixed, 95% CI
2.1.1 Doxorubicin + cisplatin (circadian timed) versus doxorubicin + cisplatin (standard timed)						
Gallion 2003	173	169	0.1 (0.114)		100%	1.07[0.86,1.34]
Subtotal (95% CI)					100%	1.07[0.86,1.34]
Heterogeneity: Not applicable						
Test for overall effect: Z=0.59(P=0.55)						
2.1.2 Doxorubicin + paclitaxel (plus filgrastin) versus doxorubicin + cisplatin						
Fleming 2004b	160	157	0 (0.124)		100%	1[0.78,1.28]
Subtotal (95% CI)					100%	1[0.78,1.28]
Heterogeneity: Not applicable						
Test for overall effect: Not applicable						
2.1.3 Docetaxel + cisplatin versus docetaxel + carboplatin						
Nomura 2010a	30	29	-0.5 (0.413)		100%	0.63[0.28,1.42]
Subtotal (95% CI)					100%	0.63[0.28,1.42]
Heterogeneity: Tau²=0; Chi²=0, df=0(P<0.0001); I²=100%						
Test for overall effect: Z=1.12(P=0.26)						
2.1.4 Paclitaxel + carboplatin versus docetaxel + carboplatin						
Nomura 2010b	29	29	0 (0.38)		100%	1[0.48,2.11]
Subtotal (95% CI)					100%	1[0.48,2.11]
Heterogeneity: Not applicable						
Test for overall effect: Z=0(P=1)						

Favours experimental 0.01 0.1 1 10 100 Favours control

Analysis 2.2. Comparison 2 Chemotherapy doublet versus chemotherapy doublet, Outcome 2 Progression-free survival.

Study or subgroup	Experimental	Control	log[Hazard Ratio]	Hazard Ratio	Weight	Hazard Ratio
	N	N	(SE)	IV, Fixed, 95% CI		IV, Fixed, 95% CI
2.2.1 Doxorubicin+ cisplatin (circadian timed) versus doxorubicin/cisplatin (standard timed)						
Gallion 2003	169	173	0.1 (0.11)		100%	1.06[0.85,1.32]
Subtotal (95% CI)					**100%**	**1.06[0.85,1.32]**
Heterogeneity: Not applicable						
Test for overall effect: Z=0.53(P=0.6)						
2.2.2 Doxorubicin + paclitaxel (with filgrastin) versus doxorubicin + cisplatin						
Fleming 2004b	160	157	0 (0.12)		100%	1.01[0.8,1.28]
Subtotal (95% CI)					**100%**	**1.01[0.8,1.28]**
Heterogeneity: Not applicable						
Test for overall effect: Z=0.08(P=0.93)						
2.2.3 Docetaxel + cisplatin versus docetaxel + carboplatin						
Nomura 2010b	29	29	-0.2 (0.301)		100%	0.83[0.46,1.49]
Subtotal (95% CI)					**100%**	**0.83[0.46,1.49]**
Heterogeneity: Tau²=0; Chi²=0, df=0(P<0.0001); I²=100%						
Test for overall effect: Z=0.64(P=0.53)						
2.2.4 Paclitaxel + carboplatin versus docetaxel + carboplatin						
Nomura 2010a	30	29	-0.1 (0.313)		100%	0.9[0.49,1.67]
Subtotal (95% CI)					**100%**	**0.9[0.49,1.67]**
Heterogeneity: Not applicable						
Test for overall effect: Z=0.33(P=0.74)						

Favours experimental 0.2 0.5 1 2 5 Favours control

Comparison 3. Single-agent chemotherapy versus other single-agent chemotherapy

Outcome or subgroup title	No. of studies	No. of partici-pants	Statistical method	Effect size
1 Survival	1		Hazard Ratio (Fixed, 95% CI)	Subtotals only
1.1 Ifosfamide versus cyclophos-phamide	1	74	Hazard Ratio (Fixed, 95% CI)	1.49 [0.74, 3.01]
2 Progression-free survival	1		Hazard Ratio (Fixed, 95% CI)	Subtotals only
2.1 Ifosamide versus cyclophos-phamide	1	74	Hazard Ratio (Fixed, 95% CI)	1.12 [0.67, 1.89]

Analysis 3.1. Comparison 3 Single-agent chemotherapy versus other single-agent chemotherapy, Outcome 1 Survival.

Study or subgroup	Experi-mental	Control	log[Hazard Ratio]	Hazard Ratio	Weight	Hazard Ratio
	N	N	(SE)	IV, Fixed, 95% CI		IV, Fixed, 95% CI
3.1.1 Ifosfamide versus cyclophosphamide						
Pawinski 1999	38	36	0.4 (0.359)		100%	1.49[0.74,3.01]
Subtotal (95% CI)					100%	**1.49[0.74,3.01]**
Heterogeneity: Tau²=0; Chi²=0, df=0(P<0.0001); I²=100%						
Test for overall effect: Z=1.11(P=0.27)						

Favours experimental 0.2 0.5 1 2 5 Favours control

Analysis 3.2. Comparison 3 Single-agent chemotherapy versus other single-agent chemotherapy, Outcome 2 Progression-free survival.

Study or subgroup	Experi-mental	Control	log[Hazard Ratio]	Hazard Ratio	Weight	Hazard Ratio
	N	N	(SE)	IV, Fixed, 95% CI		IV, Fixed, 95% CI
3.2.1 Ifosamide versus cyclophosphamide						
Pawinski 1999	38	36	0.1 (0.266)		100%	1.12[0.67,1.89]
Subtotal (95% CI)					100%	**1.12[0.67,1.89]**
Heterogeneity: Not applicable						
Test for overall effect: Z=0.43(P=0.67)						

Favours experimental 0.2 0.5 1 2 5 Favours control

ADDITIONAL TABLES

Table 1. Comparison 1: More versus less chemotherapy: response rates, progression-free survival and overall survival

Study	Patients ran-domised (patients analysed)	Median age (years) (range)	Type of patients	ORR (%)	Medi-an PFS (months)	Medi-an OS (months)
Horton 1982						
Megestrol, cyclophos-phamide, doxorubicin	64 (64)	63 (42-85)	Stage III-IV, recurrent or metastatic	23%	NR	NR
Megestrol, cyclophos-phamide, doxorubicin, 5-FU	67 (67)	65 (37-81)		13%	NR	NR
Aapro 2003						
Doxorubicin	87 (87)	63 (41-76)	Advanced or recurrent	17%	†7	7
Doxorubicin, cisplatin	90 (90)	63 (40-76)		43%	†8	9
Cohen 1984						

Table 1. Comparison 1: More versus less chemotherapy: response rates, progression-free survival and overall survival *(Continued)*

Melphalan, 5-FU, megestrol acetate	146 (126)	63 (33-82)	Stage III-IV or recurrent	38%*	†6	11
Doxorubicin, cyclophosphamide, 5-FU, megestrol acetate	149 (131)			36%**	†5	10
Edmonson 1987						
Cisplatin	14 (14)	64 (41-78)	Progestin-refractory, Stage III-IV metastatic	21%	1.8	7.4
Cisplatin, doxorubicin, cyclophosphamide	16 (16)	66 (52-79)		31%	2.9	6.6
Fleming 2004a						
Doxorubicin, cisplatin	136 (129)	NR (≤ 50 to 81)	Stage III-IV or recurrent	34%	5.3	12.3
Doxorubicin, cisplatin, paclitaxel	137 (134)			57%	8.3	15.3
Long 2006						
Doxorubicin, cyclophosphamide	15 (15)	65 (49-77)	Advanced, recurrent or metastatic	26%	6.2	15
Doxorubicin, cyclophosphamide, methotrexate, vinblastine	13 (13)	67 (37-79)		69%	6.9	15
Thigpen 1994						
Doxorubicin	171 (132)	65.1 (36-90)	Advanced or recurrent	22%	†3.2	6.9
Doxorubicin, cyclophosphamide	185 (144)	65.0 (43-83)		30%	†3.9	7.3
Thigpen 2004						
Doxorubicin	150 (150)	66.9 (NS)	Stage III-IV or recurrent	25%	5.7	9.0
Doxorubicin, cisplatin	131 (131)	64.4 (NS)		42%	3.8	9.2

5-FU: 5-fluorouracil; ORR: objective response rate; PFS: progression-free survival, OS: overall survival; NR: not reported
* response based on 77 patients; ** response based on 78 patients
† Based on time to progression not PFS

Table 2. Comparison 2: Doublet versus doublet chemotherapy: response rates, progression-free survival and overall survival

Study	Patients randomised (patients analysed)	Median age (years) (range)	Type of patients	ORR (%)	Median PFS (months)	Median OS (months)

Table 2. Comparison 2: Doublet versus doublet chemotherapy: response rates, progression-free survival and overall survival *(Continued)*

Fleming 2004b						
Doxorubicin, cisplatin	160 (157)	NR (≤ 60 - ≥71)**	Stage III-IV or recurrent	40%	7.2	12.6
Doxorubicin, paclitaxel, filgrastim	168 (160)			43%	6.0	13.6
Gallion 2003						
Standard timed doxorubicin + cisplatin	175 (169)	65 (≤ 50 to 81)	Stage III-IV, persistent or recurrent	46%	6.5	11.2
Circadian timed doxorubicin + cisplatin	177 (173)			49%	5.9	13.2
Weber 2003						
Doxorubicin, cisplatin	34 (29)	64 (44-75)	Advanced or recurrent	27.6%	*6.7	NR
Carboplatin, paclitaxel	36 (34)			35.3%	*7.7	NR
Nomura 2010a						
Docetaxel, carboplatin	30 (29)	66 (54-73)	Advanced, recurrent or metastatic	51.7%	7.6	20.7
Docetaxel, cisplatin	30 (29)	64 (39-74)		48.3%	7.8	24
Nomura 2010b						
Docetaxel, carboplatin	30 (29)	66 (54-73)	Advanced, recurrent or metastatic	51.7%	7.6	20.7
Paclitaxel, carboplatin	30 (30)	61 (49-74)		60.0%	9.5	28.1

ORR: objective response rate; PFS: progression-free survival; OS overall survival; NR: not stated reported
* Time to progression (not PFS)
** Report states that age was not well balanced by treatment arm

Table 3. Comparison 3: Single-agent versus single-agent chemotherapy: response rates, progression-free survival and overall survival times

Study	Patients randomised (patients analysed)	Median age (years) (range)	Type of patients	ORR (%)	Median PFS (months)	Median OS (months)
Horton 1978						
Doxorubicin	21 (21)	NR	Local extension or metastases	19%	NR	NR
Cyclophosphamide	19 (19)			0%	NR	NR
Pawinski 1999						
Cyclophosphamide	36	62.5 (45-73)	Recurrent or metastatic	7%	1.6	NR

Table 3. Comparison 3: Single-agent versus single-agent chemotherapy: response rates, progression-free survival and overall survival times *(Continued)*

Ifosfamide	38	61.0 (40-70)	12%	1.8	NR

ORR: objective response rate; PFS: progression-free survival; OS overall survival; NR: not stated reported

APPENDICES

Appendix 1. CENTRAL search strategy

#1 MeSH descriptor Endometrial Neoplasms explode all trees
#2 endometr* near/5 (cancer* or tumor* or tumour* or neoplas* or malignan* or carcinom* or adenocarcinom*) #3 uter* and lining and (cancer* or tumor* or neoplas* or malignan* or carcinom* or adenocarcinom*)
#4 (#1 OR #2 OR #3)
#5 advanced or metasta* or recurren*
#6 (#4 AND #5)
#7 Any MeSH descriptor with qualifier: DH
#8 chemotherap*
#9 MeSH descriptor Antineoplastic Agents explode all trees
#10 MeSH descriptor Antineoplastic Combined Chemotherapy Protocols explode all trees
#11 cytotoxic*
#12 doxorubicin*
#13 adriamycin*
#14 doxil*
#15 rubex*
#16 epirubicin*
#17 pharm*rubicin*
#18 ellence*
#19 hydroxydoxorubicin*
#20 hydroxydaunorubicin*
#21 cyclophosphamide*
#22 cytoxan*
#23 neosar*
#24 ctx*
#25 cisplatin*
#26 platinol*
#27 cddp*
#28 carboplatin*
#29 paraplatin*
#30 cbdca*
#31 ifosfamide*
#32 ifex*
#33 isophosphamide*
#34 paclitaxel*
#35 taxol*
#36 taxane*
#37 (#7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 OR #18 OR #19 OR #20 OR #21 OR #22 OR #23 OR #24 OR #25 OR #26 OR #27 OR #28 OR #29 OR #30 OR #31 OR #32 OR #33 OR #34 OR #35 OR #36)
#38 (#6 AND #37)

Appendix 2. MEDLINE search strategy

Medline Ovid

1 exp Endometrial Neoplasms/
2 (endometr* adj5 (cancer* or tumor* or tumour* or neoplas* or malignan* or carcinom* or adenocarcinom*)).mp.
3 (uter* and lining and (cancer* or tumor* or tumour* or neoplas* or malignan* or carcinom* or adenocarcinom*)).mp.
4 1 or 2 or 3
5 (advanced or metasta* or recurren*).mp.
6 4 and 5

7 drug therapy.fs.
8 chemotherap*.mp.
9 exp Antineoplastic Agents/
10 exp Antineoplastic Combined Chemotherapy Protocols/
11 cytotoxic*.mp.
12 doxorubicin*.mp.
13 adriamycin*.mp.
14 doxil*.mp.
15 rubex*.mp.
16 epirubicin*.mp.
17 pharm?rubicin*.mp.
18 ellence*.mp.
19 hydroxydoxorubicin*.mp.
20 hydroxydaunorubicin*.mp.
21 cyclophosphamide*.mp.
22 cytoxan*.mp.
23 neosar*.mp.
24 ctx*.mp.
25 cisplatin*.mp.
26 platinol*.mp.
27 cddp*.mp.
28 carboplatin*.mp.
29 paraplatin*.mp.
30 cbdca*.mp.
31 ifosfamide*.mp.
32 ifex*.mp.]
33 isophosphamide*.mp.
34 paclitaxel*.mp.
35 taxol*.mp.
36 taxane*.mp.
37 or/7-36
38 6 and 37
39 randomized controlled trial.pt.
40 controlled clinical trial.pt.
41 randomized.ab.
42 placebo.ab.
43 drug therapy.fs.
44 randomly.ab.
45 trial.ab.
46 groups.ab.
47 or/39-46
48 38 and 47
49 (animals not (humans and animals)).sh.
50 48 not 49

key:
mp = title, original title, abstract, name of substance word, subject heading word
fs = floating subheading
ab = abstract
pt = publication type
sh = subject heading

Appendix 3. EMBASE search strategy

Embase Ovid

1 exp endometrium tumor/
2 (endometr* adj5 (cancer* or tumor* or tumour* or neoplas* or malignan* or carcinom* or adenocarcinom*)).mp.
3 (uter* and lining and (cancer* or tumor* or tumour* or neoplas* or malignan* or carcinom* or adenocarcinom*)).mp.
4 1 or 2 or 3
5 (advanced or metasta* or recurren*).mp.
6 4 and 5
7 dt.fs.

![Cochrane Library logo] Cochrane
Library

Trusted evidence.
Informed decisions.
Better health.

Cochrane Database of Systematic Reviews

8 chemotherap*.mp.
9 exp antineoplastic agent/
10 cytotoxic*.mp.
11 doxorubicin*.mp.
12 adriamycin*.mp.
13 doxil*.mp.
14 rubex*.mp.
15 epirubicin*.mp.
16 pharm?rubicin*.mp.
17 ellence*.mp.
18 hydroxydoxorubicin*.mp.
19 hydroxydaunorubicin*.mp.
20 cyclophosphamide*.mp.
21 cytoxan*.mp.
22 neosar*.mp.
23 ctx*.mp.
24 cisplatin*.mp.
25 platinol*.mp.
26 cddp*.mp.
27 carboplatin*.mp.
28 paraplatin*.mp.
29 cbdca*.mp.
30 ifosfamide*.mp.
31 ifex*.mp.
32 isophosphamide*.mp.
33 paclitaxel*.mp.
34 taxol*.mp.
35 taxane*.mp.
36 or/7-35
37 6 and 36
38 exp controlled clinical trial/
39 randomized.ab.
40 placebo.ab.
41 dt.fs.
42 randomly.ab.
43 trial.ab.
44 groups.ab.#
45 or/38-44
46 37 and 45

key:
mp = title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name
fs = floating subheading
ab = abstract

WHAT'S NEW

Date	Event	Description
11 February 2015	Amended	Contact details updated.

HISTORY

Protocol first published: Issue 4, 2002
Review first published: Issue 3, 2005

Date	Event	Description
27 March 2014	Amended	Contact details updated.
11 July 2012	Amended	Author details amended.
4 July 2012	New citation required but conclusions have not changed	Literature searches updated up to January 2012. Four new studies added but conclusions not changed.
10 May 2012	New search has been performed	Text of the review revised.
14 June 2005	New citation required and conclusions have changed	Substantive amendment

CONTRIBUTIONS OF AUTHORS

CV appraised the updated search results for relevant eligible trials, extracted data from published trials, completed the final analyses of all outcomes and updated the text of the review for this update.

JT prepared the data extraction forms, extracted data and obtained unpublished data from investigators for the original review that was also used in this update. She also advised on the conduct of the analyses for this update, helped with interpretation of the results and preparation of the final manuscript.

SB appraised the updated search results for relevant eligible trials, assisted with data extraction, sought additional unpublished summary data from investigators and conducted preliminary survival and PFS analyses for this updated review.

PS helped with the interpretation of the results and with the preparation of the final manuscript.

DECLARATIONS OF INTEREST

None known.

SOURCES OF SUPPORT

Internal sources

- Medical Research Council, UK.
- NHS R&D, UK.
- Macmillan Cancer Relief, UK.
- University of Liverpool, UK.
- University of Leicester, UK.

External sources

- No sources of support supplied

INDEX TERMS

Medical Subject Headings (MeSH)

Antineoplastic Agents [adverse effects] [*therapeutic use]; Antineoplastic Combined Chemotherapy Protocols [*therapeutic use]; Endometrial Neoplasms [*drug therapy] [pathology]; Neoplasm Recurrence, Local [*drug therapy] [pathology]; Randomized Controlled Trials as Topic

MeSH check words

Female; Humans